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THE ROLE OF MIR-34A IN INHIBITION OF PROSTATE TUMOR
GROWTH IN THE BONE AND INDUCTION OF AUTOPHAGY

Sanchaika Gaur, B.S.
Supervisory Professor: Gary E. Gallick, Ph.D.

Prostate cancer (PCa) is the second leading cause of cancer-related deaths in men in the
United States, with most deaths occurring from bone metastasis. Several new therapies have
been FDA approved for bone-metastatic PCa, but patient survival has only marginally
improved due to therapy resistance, which often arises from constitutive activation of
compensatory signaling pathways. This dissertation work focused on a mechanistic
understanding of how cross talk between tyrosine kinase receptors contributes to therapy
resistance, and how this may be overcome by downregulating expression of these receptors.
In PCa cell lines and xenograft models, I demonstrated that activation of IGF-1R receptor
tyrosine kinase (RTK) through IGF-1 leads to delayed, ligand-independent activation of
another RTK, MET, that requires Src activation and transcription, suggesting that
downregulation of expression of these kinases may be required for better inhibition of their
functions.
I therefore examined the biologic effects of overexpression of miR-34a, a tumor suppressive
microRNA that downregulates multiple proteins involved in PCa progression. I demonstrated
v

that miR-34a is downregulated in high metastatic PCa cell lines, concomitant with its targets
being overexpressed. Overexpression of miR-34a decreased several properties associated
with metastasis, including-migration, invasion, and proliferation. I next demonstrated that
miR-34a delivery to xenografts grown in the femurs of immunocompromised mice inhibited
prostate tumor growth and preserved bone integrity.
To examine the mechanisms by which miR-34a overexpression inhibited cancer growth,
autophagy and apoptosis pathways were studied. I determined the expression of autophagy
markers and the requirement of key signaling intermediates in the autophagic pathway upon
miR-34a overexpression. I demonstrated that miR-34a overexpression induced apoptosis
along with a non-canonical form of autophagy that is independent of ATG5, ATG7 and
Beclin-1 expression.
In summary, studies in this dissertation provide evidence for IGF-1/1R induced ligandindependent MET activation, suggesting that cross talk among receptors may be responsible
for resistance to targeted therapies. To potentially overcome this problem, I demonstrated
that delivery of miR-34a that downregulates proteins involved in PCa progression decreases
tumor growth in the bone. Overexpression of miR-34a induces apoptosis and a novel form of
autophagy that might contribute to its therapeutic effects.
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Chapter 1
Introduction
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Overview of Prostate Cancer
Prostate cancer (PCa) is the second most prevalent cancer in men in the United States
[1, 2]. It is estimated that in 2014 there will be 233,000 new cases and 29,480 deaths will
occur from PCa [1]. Improvements in diagnostic methods that aid in early detection and
successful surgical intervention and/or radiation therapy have led to nearly 100% five-year
survival rate for patients with localized tumor [1, 2]. However, five-year survival rates drops
to 28% with the development of distant metastasis [1], which is most common in the bone,
followed by lungs, liver and brain [3]. Bone metastasis contributes to 90% of the deaths from
PCa due to lack of effective treatment approaches [4]. Early stage prostate cancer cells are
dependent on androgens for their survival and proliferation and androgen-ablation therapies
are effective treatment modalities at this stage. However, most patients with advanced stage
cancer develop progressive disease even with castrate levels of androgens leading to
metastatic castrate-resistant prostate cancer (mCRPC) [5].
Increasing age is the only well-established risk factor for PCa with 60% of the cases
being diagnosed in men 65 years of age and older [2]. Other risk factors associated with PCa
include, family history, inherited genetic conditions (such as Lynch syndrome and BRAC2
mutation), obesity, high diary and processed meat diet, and African ancestry [2, 6]. Some of
these risk factors might contribute to higher incidence rates for prostate cancer in African
American men than in non-Hispanic white men [2]. Thus, it is important to better understand
the genetic, epigenetic and molecular alterations in progressive PCa as well as the tumor
microenvironment interactions that promote cancer survival and progression for development
of successful treatment modalities for advanced disease.
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Pathology of Prostate Cancer
The prostate gland is a part of male reproductive system responsible for producing
and storing one third of the seminal fluid. Adult prostate is an acorn-shaped gland, located
below the bladder comprising of three cell types: luminal, basal and neuroendocrine cells.
Luminal cells, the major constituents of the gland, carry out secretory functions, express lowmolecular weight cytokeratins (CK8/18), express androgen receptor and are dependent on
androgen signaling [6, 7]. Androgens are required for normal prostate function as they bind
to androgen receptor (AR) that then translocates to the nucleus and control transcriptional
expression of androgen-regulated genes that are required for production of seminal fluids [8].
The basal cells are aligned between luminal cells and the basement membrane and thought to
serve as a barrier to protect luminal cells from oncogenic insults. It has been speculated that
basal cell layer has stem cell functions and basal cells can differentiate into luminal cells to
give rise to prostatic carcinomas [6, 7]. Basal cells express high-molecular weight
cytokeratins (CK5/14) and are not dependent on androgen signaling [6, 7]. Neuroendocrine
cells express synaptophysin and chromagranin A and constitute a very small fraction of the
prostate cells and are involved in secreting serotonin and other neuropeptides [9].
The cell of origin of prostate cancer is controversial with Okada et al. reporting
majority of prostate adenocarcinoma with luminal cytokeratin marker staining, suggesting
luminal cells as the origin of PCa [10]. However, cancer recurrence after anti-hormonal
therapy and progression of metastatic castrate resistant prostate cancer (mCRPC) suggest
androgen independent basal cells as the cell of origin [7]. Furthermore, Verhagen et al.
identified an intermediate cell population with basal and luminal markers in the primary PCa
and hormone-independent PCa [11] and upregulation of prostate stem cell antigen (PSCA), a
3

marker for intermediate cells in prostate cancer suggests intermediate cells as the cell of
origin [7]. The work of Choi, et al. identified that both luminal and basal cell population have
self-renewal abilities leading to cancer initiation in a Pten-null mouse model further
demonstrating that basal cells are capable of differentiating into luminal cells and suggesting
the role of basal-luminal differentiation for prostate cancer initiation [12].
McNeal, et al. in their seminal paper defined three distinct morphological regions in the
human prostate, which are the peripheral zone, the transition zone and the central zone [13].
The non-malignant Benign Prostatic Hyperplasia (BPH) occurs mostly in the transition zone
while prostate carcinoma occurs mainly in the peripheral zone [13, 14].
Prostate cancer is pathologically classified by morphological criteria based on sum of
Gleason score and clinically by TNM staging. The Gleason grading system takes into
account appearance of the architecture of prostate cancer cells under the microscope and
assigns primary and secondary Gleason grades to the most prevalent and second most
prevalent pattern of the tumor specimen [15]. The Gleason grades range from 1 to 5, and
Gleason score is determined by the sum of primary and secondary grade. The Gleason scores
thus, range from 2 to10, with higher score indicative of poorly differentiated cells and more
advanced cancer. A Gleason score of 8-10 has higher risk of cancer recurrence, metastasis
and death [16]. In addition to the morphology of the cells, the TNM staging system, which
evaluates the size and range of the primary tumor (T), the involvement of lymph nodes (N)
and the degree of distant metastasis (M) is also widely used by clinicians to predict survival
and prognosis with higher staging indicative advanced cancer. The morphological grading
and clinical staging system lacks the incorporation of molecular heterogeneity that drives
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disease progression and thus, targeted-molecular agents cannot be appropriately provided to
individual patients.

Spiral Progression Model
Recognizing the need for a classification system that includes molecular makers for
therapy selection in PCa, Logothetis et al. proposed an alternative model of PCa progression
which incorporates stage-specific molecular drivers that can be targeted by single or
combination therapies [5]. This alternative model (Fig. 1) consists of an endocrine-driven
phase, a microenvironment-driven phase and a tumor cell autonomous phase [5]. In the
endocrine driven phase, tumor growth is dependent on the androgens, testosterone (secreted
from the testes) and dehydroepiandrosterone (DHEA) (secreted from the adrenal gland),
which are converted by the enzyme 5-α-reductase (SRD5A) to dihydrotestosterone (DHT).
DHT binds to androgen receptor (AR) with higher affinity than testosterone and promotes
cancer cell proliferation and metabolism. SRD5A inhibitors (e.g., finasteride and dutasteride)
are thus effective in the treatment of low-grade endrocrine-driven cancer, while androgen
ablation therapy (e.g., Lupron) is effective in the treatment of high-grade cancers that are not
DHT-dependent [5]. The responses to these therapies are short-lived and resistance soon
develops as PCa transitions to a paracrine-driven phase and enters the progression spiral (Fig.
1) where each “turn” of the spiral is driven by molecular marker/s that can be targeted and
the “pitch” is indicates the duration of time for which the tumors are responsive to targeted
therapy. Chemotherapeutic modalities have limited success in this phase since multiple
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Figure 1 - Spiral Progression model
This alternative model describes different stages of prostate cancer. In the early stage,
prostate cancer cells are DHT-dependent. Upon entry into the progression spiral where each
turn is driven by a molecular marker/s, the cancer cells are in paracrine-driven phase. Cancer
cells can exit from the spiral and enter the cell autonomous stage.
From Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E and Lin SH
(2013). Molecular Classification of Prostate Cancer Progression: Foundation for MarkerDriven Treatment of Prostate. Cancer Discovery 3; 849. Reproduced with Permission
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factors including changes in AR signaling (AR amplification, mutation, splicing), aberrant
oncogenic activation (e.g., activation of Src family kinases, Her2, Akt), receptor
overexpression (e.g., MET, IGF-1R), downregulation of tumor suppressors (e.g, loss of
PTEN, p53) and paracrine mediated effects (activation of osteoblasts and osteoclasts) can
drive disease progression and metastatic growth [5]. This progressive disease where patients
do not respond to androgen ablation therapies is termed as metastatic castrate-resistant
prostate cancer (mCRPC). According to the alternative model described above, prostate
cancer cells can exit the spiral and enter a cell autonomous phase where the tumor is
androgen independent with neuroendocrine features. This late-stage disease is termed as
neuroendocrine prostate cancer or small cell prostate cancer or anaplastic prostate cancer.
Surprisingly, whereas earlier stages do not respond well to chemotherapy, this stage responds
to chemotherapeutic agents [5]. These distinct features of PCa progression and different
responses to therapies, present the need to better understand stages of PCa progression and
the underlying genetic, epigenetic and molecular alternations in each stage.

Genetic and Epigenetic Alterations in Prostate Cancer
There are few signature driving oncogenic mutations in PCa; however, tumor cells
undergo many genetic and epigenetic alterations that can initiate cancer development and
further promote its progression. These include copy number alterations, chromosomal
rearrangements and alterations, epigenetic silencing (DNA methylation), histone
modifications and chromatin remodeling and miRNA dysregulation. Losses of chromosomes,
including 8p, 10q, 13q and 17p have been reported [6, 17] by comparative genomic
7

hybridization (CGH), which includes regions for the tumor suppressor genes, NKX3.1,
PTEN, Rb and p53 respectively. Less frequent chromosome gains of 8q and 7 [18-20] have
also been reported which include regions for candidate oncogene c-Myc, EGFR and c-Met.
Most genomic aberrations were identified in the RB, PI3K and RAS/RAF signaling pathway
by global copy-number and transcriptome profile analysis [21]. Downregulation of tumor
suppressive gene NKX3.1, located on 8p has been implicated in prostate cancer initiation [6,
22]; loss of PTEN located on 10q is involved in PCa development and progression; while
loss of Rb and p53 are associated with invasive PCa and progression to castrate-resistant
metastatic PCa [6, 23, 24]. The gene loci of c-Myc, 8q24.21 is amplified in advanced prostate
cancer and in metastases [25], and Myc overexpression in mouse models induces cancer
initiation and progression to invasive prostate adenocarcinoma [26]. Chromosomal
rearrangements have been identified with fusion of androgen regulated TMPRSS with ETS
family of genes [27, 28], an early event in PCa development and associated with more
aggressive cancer [29].
Epigenetic modifications, in addition to genetic alterations are important in cancer
initiation and progression. DNA methylation is an epigenetic modification that occurs mostly
at the cytosines within the CpG islands, found at the 5’untranslated region (UTR) of
promoters of numerous genes. DNA promoter methylation-induced gene silencing has been
reported for more than 50 genes in PCa, including Glutathione S-transferase P1 (GSTP1)
hypermethylation in more than 90% of PCa [30-32]. Epigenetic modifications of histone
include acetylation, methylation, etc. of the histones and in prostate cancer acetylation of
H3K18 and methylation of H3K4 has been shown to be predictors of PCa progression [33].
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Molecular Mechanisms Driving Prostate Cancer Progression
Several molecular alterations can drive prostate cancer progression that includes
overexpression and/or activation of receptor and non-receptor protein tyrosine kinases
(PTKs) that promote PCa growth, development, progression, and metastasis and thus driving
each spiral of the progression model (Fig. 1). One of the genes implicated in PCa progression
and metastasis is receptor tyrosine kinase (RTK), c-Met (MET). MET can be activated by
bindings of its ligand, HGF which leads to receptor dimerization and phosphorylation of
tyrosines (Tyr), Tyr 1234 and Tyr 1235 in the kinase domain and further phosphorylation of
Tyr 1349 and Tyr 1356 in the carboxy-terminal substrate docking site leads to MET
activation and recruitment of signaling molecules [34]. MET/HGF signaling can relay
activation of downstream signaling cascades important for cell survival, proliferation,
differentiation, migration, and invasion [35]. MET expression significantly increases with
PCa progression, and increased MET expression is inversely related to poor prognosis [36].
MET is expressed in basal and intermediate cells of normal prostate and is also expressed on
PCa cells [37]. Androgen deprivation increases MET expression and also increases HGF
expression in prostate cancer and stromal cells [38, 39]. MET expression is higher in PCa
tissue compared with normal tissue and in bone metastasis compared with lymph node
metastasis of PCa [40]. MET receptor is present on stromal cells including osteoblasts,
osteoclasts and endothelial cells and its ligand HGF is also secreted by stromal cells
suggesting involvement of the MET/HGF signaling in the bone microenvironment promoting
survival and growth of tumor and stromal cells [4]. Thus, targeting of MET in advanced bone
metastatic prostate cancer has been thought to be clinically important however, single agent
MET inhibitors have not been successful in treating advanced disease [4] and multi-targeted
9

small molecule inhibitors such as Cabozatinib recently failed in Phase III clinical trial. This
could be due to emergence of compensatory pathways and/or MET re-activation in response
to inhibitors (Varkaris, unpublished) through different mechanisms that include gene
amplifications, mutations and ligand independent receptor cross talk. Integrin binding, G
protein coupled receptors, plexins, CD44, EGFR and RET have all been implicated in ligand
independent MET activation [41]. In non-small cell lung cancer (NSCLC), MET activation
through gene amplification is predicted to be one of the mechanisms of EGFR inhibitor,
gefitinib resistance [42]. In NSCLC, MET can be activated by EGF in a ligand independent
manner [43] and EGFR can activate MET to promote invasion and brain metastasis [44].
However, in PCa, gene amplifications or mutations of MET are extremely rare and receptor
cross talk mechanisms have not been previously reported. It will be thus important to
determine whether in PCa, MET can be activated by cross talk with other receptors and
interactions with soluble factors in the bone microenvironment that contributes to
development of resistance to MET inhibitors.
Axl is another receptor tyrosine kinase that can be activated by its ligand, Gas6 or
homophillic interactions [45]. Receptor dimerization leads to autophosphorylation and
activation of downstream signaling that can promote cancer cell proliferation, survival,
migration, and invasion [46, 47]. Axl expression increases with high-grade prostate cancer
and in bone metastasis of PCa [46, 48]. Axl protein and mRNA expression are also higher in
more metastatic PCa cell lines and knockdown of Axl decreases expression of mesenchymal
markers as well as decreases survival, proliferation, migration and invasion abilities of PCa
cell lines [49]. Thus, targeting Axl could be beneficial for treatment of advanced PCa.
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c-Myc (Myc) is a proto-oncogene that regulates cell proliferation and transformation.
It activates genes involved in cell cycle progression and inhibits genes that are involved in
cell cycle arrest [50]. c-Myc mRNA expression is increased in laser capture micro-dissected
(LCM) tumor cells compared to benign epithelial cells [51] and Myc is also overexpressed at
the protein level in prostate cancer cells [25]. Myc can be upregulated by AR in a ligand
independent manner in high-grade metastatic PCa [52] and can be post-transcriptionally
controlled by microRNAs [53]. In transgenic mice, Myc overexpression in the prostate can
lead to development of prostatic intraepithelial neoplasia (PIN) and followed by progression
to invasive carcinoma [26]. Myc being a transcriptional factor is hard to target by
conventional small molecule inhibitors [54], however RNAi-mediated silencing of Myc
transcription can inhibit tumor initiating capacity and stem-like maintenance of prostate
cancer cells [55] and strategies targeting Myc expression can be developed for treatment of
prostate cancer.
Since, many genes including MET, Axl, c-Myc can contribute to PCa progression,
targeting these multiple genes could be a better approach for treatment of advanced bone
metastatic cancer.

Prostate Cancer Metastasis and Tumor Microenvironment
Prostate cancer mostly commonly metastasizes to the bone, followed by lungs, liver
and brain. It is not known why prostate cancer cells preferentially metastasize to the bone.
There are some suggestions that the tumor microenvironment interactions in PCa can
promote tumor growth and metastases in the bone. The bone microenvironment consists of
11

stromal cells including bone forming osteoblasts, bone dissolving osteoclasts, fibroblasts,
endothelial cells and immune cells. Many growth factors including IGF-1, and cytokines like,
IL-6, IL-8, chemokines and extracellular matrix (ECM) proteins secreted in the bone
microenvironment act on tumor cells enhancing their growth and survival [56]. Tumor cells
also secrete factors that act upon the stromal cells and alter their properties favoring tumor
growth. Tumor cells secrete osteoblastic and osteoclastic factors including-BMPs, PTHrP,
ET-1, PDGF, that act on osteoblasts promoting new bone formation and on osteoclasts
promoting bone resorption [57, 58]. Osteoclasts and osteoblasts on the other hand secrete
growth factors including- TGF-β, HGF, IGF-1, etc. that promote tumor cell proliferation and
survival [57, 58]. Thus, it is important to target both the tumor and the microenvironment
compartments to disrupt the tumor-microenvironment interactions and have elevated
therapeutic benefit in metastatic prostate cancer.

Treatment Modalities in Prostate Cancer
Prostate cancer in its DHT-dependent stage can be treated by surgical interventions
and/or androgen deprivation therapy (ADT). First generation anti-androgens including
flutamide, bicalutamide, or first generation androgen synthesis inhibitors including
ketoconazole can be given to patients with non-metastatic CRPC [59]. However, the
responses to these therapies are heterogeneous and eventually lead to cancer progression.
FDA recently approved Abiraterone and Enzalutamide for treatment of metastatic prostate
cancer [60]. Abiraterone is a CYP17 inhibitor that inhibits androgen biosynthesis while
Enzalutamide is an androgen receptor antagonist that target androgen receptor activation
12

[60]. These agents have modest improvements in overall survival with development of
resistance and/or activation of oncogenic pathways that further drives cancer progression.
Radium 223 (Rad 223), an alpha-emitting radiopharmaceutical that targets the bone matrix is
used for treatment of bone metastasis in prostate cancer [60]. Rad 223 showed modest
improvement in overall survival by 3.7 months compared to placebo arm [60]. Small
molecule inhibitors targeting activation of RTKs (e.g., Cabozatinib for MET) or SFKs (e.g.
Dasatinib) have severe toxic side effects and are not successful in Phase III clinical trials
with mCRPC [4]. Thus, there is a need to develop therapeutic approaches that target multiple
oncogenic pathways to combat resistance as well as target both the tumor and the
microenvironment for better treatment of metastatic prostate cancer. One such approach is
through microRNAs that are deregulated in cancer and their replacement or inhibition could
affect multiple targets involved in cancer development and progression.

MicroRNAs in Cancer
Regulation through microRNAs (miRNAs) is an important post-transcriptional
mechanism present in a cell. miRNAs are 18- to 22-nucleotide (nt) post-transcriptional
modulators that regulate many normal cellular processes, including growth, survival,
differentiation, cell cycle arrest, aging; and their dysregulation has been implicated in cancer
development and progression. miRNAs are transcribed from the genome as longer primary
transcripts (pri-miRNAs) which is cleaved by ribonuclease Drosha (DGCR8) into 70-100 nt
long hairpin pre-miRNA structures with 3’overhang. These pre-miRNAs are then exported
into the cytoplasm by exportin 5 (XPO5) where the ribonuclease Dicer further cleaves the
13

hairpin pre-miRNA to ~22 nt long miRNA duplex; and following separation and degradation
of the other strand, mature miRNA is loaded in the RNA-induced silencing complex (RISC)
[61, 62]. The mature miRNA is led by the RISC and Argonaute (AGO) proteins to interact
with the target mRNA at the 3’UTR through partial complementary sequence and inhibits
protein translation by either inducing silencing or degradation of the target mRNAs [62-64]
(Fig. 2). It has been reported that miRNAs can also bind to the 5’UTR and ORF and can
directly bind to DNA to regulate gene expression at the transcriptional level [64]. Thus,
miRNA can regulate gene expression through many different mechanisms.
In cancer, miRNAs can act as oncomirs by downregulating tumor suppressor genes or
can act as tumor suppressive miRs by downregulating oncogenes. It was first reported that in
B-CLL, the loss of chromosome 13q14, which encodes for tumor suppressive miR-15a and
miR-16-1, occurs in ~68% of the cases [65]. Amplification of miR-155, an oncogenic
miRNA has been found in various B cell lymphomas and it is shown to be overexpressed in
many different hematopoietic cancers and solid tumors [66].
Differential expression of miRNA in normal vs. cancer tissue and in indolent vs.
metastatic disease can be used for targeted therapy and in biomarker development. Since, a
single miRNA can regulate multiple targets that are involved in various tumorigenic
processes, miRNA-based therapies can effectively inhibit various oncogenic pathways and
provide better treatment options than those that are currently available [63]. For example, a
miRNA that targets multiple tumor promoting genes including, MET, Axl, c-Myc in prostate
cancer discussed earlier in this introduction could be developed for therapeutic applications.

14

Figure 2 - miRNA biogenesis
miRNA is transcribed from its gene and then processed by the enzyme Drosha and exported
from the nucleus by exportin 5. In the cytoplasm, it is further cleaved by the enzyme Dicer to
get miRNA duplex and following degradation of the second strand, the mature strand is
loaded on the RISC for target mRNA recognition by complementary base pairing to inhibit
mRNA translation.
From Jansson MD and Lund AH (2012). MicroRNA and cancer. Mol. Oncol. 6(6): 590-610.
Reproduced with permission
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There are two emerging strategies for miRNA-based therapies for clinical applications. One
strategy involves inhibiting the function of oncogenic miRs by using antagonists likeantagomirs, miRNA sponge or locked-nucleic acids (LNAs) that can bind and inhibit specific
miRNAs. Another strategy involves restoring the expression of tumor suppressive miRNA
that is downregulated in cancer cells. This can be achieved by delivering mature miRNA
mimics through polymer, neutral lipid-based or cationic nanoparticle-based approaches [63].
miRNA replacement therapy is advantageous because the miRNA mimics are very small in
size and can be effectively encapsulated and delivered through systemic injections [63]. The
mimics have the same sequence as the miRNA that is downregulated in cancer and are
expected to behave in a similar manner thus, eliminating nonspecific off-targets effects [63].
A single tumor suppressive miRNA can inhibit multiple oncogenic pathways for example;
let-7 can inhibit Myc, Ras, cyclin D, CDK6 that are involved in promoting oncogenic
transformation and cancer cell proliferation [63]. Pre-clinical studies using miRNA delivery
have been effective in decreasing tumor growth without toxic side effects in animal models
of various cancers. Polyethylenimine (PEI)-mediated systemic delivery of miR-145 and miR33a reduced tumor growth in a mouse model of colon cancer [67]. Atelocollagen mediated
systemic delivery of miR-16 inhibited prostate tumor growth in the bone in an intra-cardiac
mouse model [68]. Several approaches including nanoparticle-mediated delivery are
currently being tested in pre-clinical miRNA therapeutic studies.
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Chitosan Nanoparticles for Therapeutic Applications
Nanoparticles are effective delivery vehicles that can be used for delivering drugs or
small RNAs through oral or systemic injections. There are liposomal, solid-lipid, silica,
carbon-based and polymeric nanoparticles, each with its unique properties that have the
potential for clinical application. Chitosan is a polysaccharide derived from deacetylation of
chitin, which is present in the naturally in fungal cell walls and crustaceans shells [69].
Chitosan consists of repeating units of glucosamine and N-acetyl-glucosamine and is
insoluble at neutral pH but becomes positively charged and soluble at acidic pH [69].
Chitosan is a naturally occurring biodegradable, biocompatible, non-toxic, low immunogenic
polymer and due to its positive charge can effectively bind cell membranes, thus increasing
cellular permeability [69, 70]. Chitosan nanoparticles can be formulated by incorporating a
polyanion like tripolyphosphate (TPP) into a solution through constant stirring [71]. Further
modifications, for e.g., including polyethylene glycol (PEG) can increase its solubility and
lead to formulation of cross-linked chitosan nanoparticles for delivering drug combinations
for therapeutic applications [72]. Han et al. demonstrated that chitosan nanoparticle can be
used for selective delivery in an orthotopic model of ovarian cancer, and silencing of growthpromoting genes by siRNAs delivered through these nanoparticles result in inhibition of
tumor growth [70]. Chitosan nanoparticles were used for combination delivery of miR-200
family members that decreased tumor growth and metastasis in different cancer models by
inhibiting angiogenesis [73]. Recently, it was shown that systemic delivery of miR-34a
through chitosan nanoparticles decreased bone metastasis in a breast cancer and melanoma in
vivo model [74]. Thus, chitosan nanoparticles have been effectively used for small RNAs
delivery in preclinical models and their physiological properties including biocompatibility
17

and low toxicity makes them an attractive delivery approach for miRNA therapy
applications.

Role of miR-34a in cancer
Expression of tumor suppressive miRNA, miR-34 is decreased in several cancers.
The miR-34 has three family members: miR-34a, miR-34b and miR-34c that share ~80%
homology in their seed sequence leading to targeting similar genes and having redundant
functions. However, the expression of miR-34 family members differs in tissue types. miR34a is more prevalent than other family members in normal human tissues, except, lung,
ovary, testes and trachea [75]. The miR-34a gene is located on chromosome 1p3622 while
miR-34b and miR-34c are transcribed from polycistronic transcript on chromosome 11q23.1.
Both of these gene loci are frequently downregulated in hematopoietic cancers and miR-34a
expression is downregulated in many solid tumors including-breast, lung, prostate, liver and
pancreatic cancers [66, 75, 76]. Expression of miR-34 family members can be induced in a
p53-dependent [77, 78] and p53 independent manner in different cell types and under
different conditions [79, 80]. The promoters of miR-34 can be hypermethylated in different
cancers leading to their downregulation. For example, miR-34a methylation was detected in
~45% of colon cancer samples and associated with liver metastasis [81]. miR-34a can
directly target and repress multiple oncogenic proteins including MET, Axl, c-Myc, Notch-1,
JAG-1, Bcl-2, SIRT-1, CDK4 (Fig. 3) in different cancers like breast, prostate, hepatocellular
carcinoma, NSCLC, among others [45, 53, 75, 82, 83]. These results suggest that there are
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Figure 3 - Role of miR-34a in cancer
miR-34a belong to the miR-34 family and is transcribed from Chr1p36.22 while its other
family members are transcribed from gene locus at Chr11q23.1. miR-34a targets and
downregulates many genes involved in various pathways promoting cancer development and
progression.
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multiple mechanisms through which miR-34a expression can be downregulated in cancers
which leads to upregulation of its targets that can then promote oncogenic transformation,
cell cycle, proliferation, survival, cancer stemness, metastasis and chemoresistance [75] (Fig.
3). Thus, miR-34a replacement therapy could be an attractive strategy to inhibit tumor
growth. Liu et al. showed that miR-34a was downregulated in CD44+ prostate cancer cells
and it targets CD44 in prostate cancer stem cells (CSCs) [84]. They further show that miR34a replacement therapy can inhibit tumor growth in an orthotopic model of PC3cells and
lung metastasis in LAPC9 model [84]. Systemic delivery of miR-34a in a lipid-based vehicle
decreased tumor growth without toxic side effects in a subcutaneous model NSCLC and
decreased expression of its targets –MET, CDK4 and Bcl2 [85]. In another study, neutral
lipid emulsion based systemic delivery of miR-34a decreased NSCLC growth in an
orthotopic and KRAS driven transgenic model [86] and in Kras/p53 double transgenic mouse
model by inhibiting known miR-34a targets [87]. In another mouse model of multiple
myeloma, miR-34a delivery decreased tumor growth and enhanced survival by decreasing
cell proliferation and inducing apoptosis [88]. These works have led to the development of
miR-34a formulation in liposomal injection, MRX34 in Phase I clinical trial for the treatment
of primary liver cancer.
In prostate cancer, miR-34a has been shown to be downregulated in prostate cancer
compared to normal tissue in laser capture microdissected (LCM) specimens [53] and its
expression decreases with increasing gleason score in FFPE samples [89]. Overexpression of
miR-34a decreases expression of AR, Notch-1 [90], c-Myc [53], MET, CD44 [84] in prostate
cancer cells and decreases cancer cell aggressiveness, inhibits proliferation, migration,
invasion, and decreases orthotopic tumor growth along with inducing apoptosis [75] (Fig. 3).
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The role of miRNAs in regulating autophagy, a process involved in cell death and/or survival
is emerging with Liu et al. reporting that miR-34a inhibits autophagy and promotes cell death
in retinoblastoma cells [91]. However, autophagic process described below is a complex
network of numerous interacting proteins and several forms of autophagy with diverse
biological effects in cancer are being discovered.

Autophagy in Cancer
Autophagy is a cellular degradation process, which is induced in response to
starvation or stress and leads to clearance of damaged proteins and cellular components [92].
Autophagic process induction begins with the formation of phagophore and following
nucleation which involves the class III phosphatidylinositol 3-kinase (PtdIns3k) complex
(containing VPS34, Beclin-1, AMBRA-1, ATG14 or UVRAG and BIF1), the vesicle
elongates to include cytosolic proteins and organelles (Fig. 4). Vesicle elongation involves
conjugation of phosphatidylethanolamine (PE) to LC3 to form LC3II that is attached on the
phagophore and helps in phagophore expansion and recognition of cargo. The phagophore
then matures into double-layered autophagosomes (AP) that can fuse with the lysosomes to
form single layered autolysosomes (AL) (Fig. 4). The lysosomal enzymes lead to vesicle
breakdown and degradation of engulfed components. This process requires coordinated
network of many essential autophagic genes including –Beclin 1, ATG5 and ATG7 among
others. However, Beclin-1, ATG-5 and ATG-7- independent autophagy has also been
reported in the literature [93-95]. It is widely accepted that this cellular “self-eating” and
evolutionary conserved mechanism promotes survival under cellular stress. However,
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Figure 4 - Autophagic Process
In canonical autophagy, induction of autophagy from stress, nutrient starvation or other
conditions leads to nucleation of lipid bilayer to form phagophore, which then elongates to
include cytoplasmic components and organelles to form double layered autophagosomes
which can then fuse with lysosomes to form single layered autolysosomes where the
engulfed components are degraded by lysosome enzymes.
From Kang R, Zeh HJ, Lotze MT and Tang D (2011) The Beclin 1 network regulates
autophagy and apoptosis. Cell Death and Differentiation 18, 571–580. Reprinted with
permission.
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in the context of cancer, autophagy has been implicated to play a tumor promoting as well as
a tumor suppressive role.
Autophagy can be induced in cancer cells as a survival mechanism in response to
nutrient deprivation, hypoxia, chemotherapeutic and other metabolic stress [92, 96].
Autophagy defects are also found in cancers with loss of essential autophagy gene beclin1
reported in prostate, breast and ovarian cancer. Loss of beclin-1 and atg5 can promote
tumorigenesis in different mouse models [96]. Autophagy can induce cell death independent
of apoptosis and has been reported as a cell death mechanism in apoptosis deficient cells. It
has been shown that prolonged treatment with targeted molecular therapy can induce
autophagy leading to cell death. In ovarian cancer, inhibition of prolactin (PRL) and its
receptor PRLR leads to non-canonical Beclin-independent destructive autophagy [97].
Inhibition of Akt in sorafenib-resistant HCC can switch protective autophagy to destructive
death promoting mechanism [98] while Rottlerin can induce autophagy leading to apoptosis
in breast cancer stem cells (CSCs) [99]. In prostate cancer, CCL2 protects PC3 cells from
autophagic cell death prolonging their survival in serum-starved conditions through
PI3K/Akt/survivin pathway and inhibition of this pathway decreases cell survival [100].
Thus, autophagy can lead to cell death along with or without apoptosis in different cancer
cell lines.

Autophagy Regulation by MicroRNAs
miRNAs have been implicated in the regulation of autophagy either directly by
targeting mRNAs of autophagic genes or indirectly by modulating autophagy inducers and
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repressors [101, 102]. miR-101 can inhibit autophagy by targeting ATG4D and RAB5A
involved in nucleation and elongation of vesicles while miR-30a can target BECN1 and
reduce rapamycin and cisplatin induced autophagy [101, 103]. While most of the studies
have focused on negative regulation of miRNAs on autophagy induction, Tazawa, et al.
reported that miR-7 induces autophagy leading to cell death by downregulating EGFR [104].
Under starvation and chemotherapy conditions, miR-34a has been reported to inhibit
autophagy by downregulating HMGB1 and promoting cell death [91]. However,
downregulation of miR-34a targets including MET and Axl can induce autophagy along with
apoptosis in certain cell lines [105, 106] though the mechanism of autophagy induction is not
known. It is thus, important to further understand the mechanism and the biological effects of
miR-34a-induced autophagy with the introduction of miR-34a therapy in clinical trials.
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Summary of Problem and Hypotheses
Prostate cancer is the second most lethal cancer with most deaths resulting from bone
metastasis. Several factors including genetic and epigenetic changes leading to multiple
molecular alterations contribute to prostate cancer initiation and progression. While organ
confined early-stage disease can be treated with androgen ablation or surgical interventions;
metastatic disease has dismal survival rates. It is thus essential to develop more effective
therapeutic approaches for treatment of advanced disease.
Numerous receptor tyrosine kinases (RTKs) are overexpressed in prostate cancer
including, MET, IGF1R, Axl and Her2 that play a role in PCa progression. However, it is not
known whether these RTKs cross talk and activate downstream signaling pathways in
prostate cancer. One of the goals of this Ph.D. dissertation work was to understand the
involvement and interactions of RTKs implicated in prostate cancer. I focused on RTK, MET
that is overexpressed in PCa by studying its activation through another RTK overexpressed
in PCa, IGF-1R that promotes cancer survival and proliferation. I hypothesized that
activation IGF-1/1R pathway leads to ligand independent MET activation in prostate cancer
cell lines. I tested this hypothesis in Chapter 3 by determining MET activation and its effects
on downstream signaling components after IGF-1/1R pathway activation.
Activation of multiple oncogenic pathways that drive cancer progression asserts the
need for therapeutic approaches that target different pathways involved in cancer
development and growth. Tumor suppressive miRNA, miR-34a is downregulated in many
cancers and targets some of the genes implicated in prostate cancer including RTKs, MET
and Axl. The second goal of this Ph.D. dissertation was to determine whether miR-34a
delivery decreases tumor growth. I hypothesized that decreased miR-34a expression leads to
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upregulation of targets that promote PCa progression, and thus in vivo miR-34a replacement
therapy could be a novel strategy for treating advanced PCa. I tested this hypothesis by
determining miR-34a expression in PCa cell lines and by delivering miR-34a through
chitosan nanoparticles in in vivo models (Chapter 4 and 5).
Several studies report that autophagy, involved in clearance of damaged organelles
and proteins, plays a critical, albeit complex role in cancer. There is evidence for tumor
promoting as well as tumor suppressive role of autophagy in cancer. Autophagy and
apoptosis can occur simultaneously or exclusively and promote cancer cell death as
demonstrated by downregulation of miR-34a targets-Axl and MET that induce autophagy
and apoptosis in cell line models. The third goal of this Ph.D. dissertation work was to
determine whether miR-34a induces autophagy. To address this question, I performed miR34a overexpression in multiple cell lines and further knocked down essential genes involved
in the autophagic pathway to determine the mechanism of miR-34a-induced autophagy
(Chapter 6 and 7).
The work in this dissertation has led to the understanding that MET may be activated
by multiple receptor tyrosine kinase receptors, and multi-targeting of these receptors may be
important therapeutically. The work in this dissertation further presents miR-34a delivery as
an alternative strategy for treatment of bone metastatic prostate cancer for which current
therapies are not very effective. Finally, this work identified a novel role of miR-34a in
inducing a non-canonical form of autophagy that occurs along with apoptosis and is involved
in promoting cell death.
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Chapter 2
Materials and Methods
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This Chapter is partly based upon “Varkaris A*, Gaur S*, Parikh NU, Song JH, Dayyani F,
Jin JK, Logothetis CJ, and Gallick GE (2013) Ligand-independent Activation of MET
Through IGF-1/IGF-1R Signaling. Int J Cancer. 2013 Oct 1;133(7):1536-46”, with
permission from International Journal of Cancer and Wiley.
* Equal contribution, shared first authorship.

Materials and Methods:
Cell lines and media:
PC3 and PC3MM2 cells were a gift from Dr. Isiah Fidler’s laboratory at MD Anderson.
LNCaP and MDA MB 231 cells were purchased from American Type Culture Collection,
and C42B4 and PC3MM2-LG (luciferase-GFP labeled) cells were a gift from Dr. Sue Hwa
Lin’s laboratory at MD Anderson. A549 were a gift from Dr. John Heymach, HepG2 were a
gift from Dr. Mein Chie Hung and SKOV3 cells were provided by Dr. Anil Sood’s
laboratory at MD Anderson. PC3 cells with doxycycline inducible shRNA knockdown of
ATG7 (PC3 shATG7 no Dox/+Dox) were provided by Dr. Daniel Frigo’s laboratory at
University of Houston. PC3, PC3MM2, A549, HepG2 and MDA MB 231 cells were
maintained in Dulbecco’s modified Eagle medium nutrient mixture F-12 (DMEM/F12,
Sigma, St. Louis, MO) with 10% fetal bovine serum (Sigma, St. Louis, MO) and 1%
penicillin/streptomycin (Hyclone, Logan, UT). LNCaP cells were cultured in RPMI-1640
media (Sigma, St. Louis, MO) with 10% fetal bovine serum (FBS), supplements (sodium
pyruvate, non-essential amino acids, and modified Eagle medium vitamin solution;
Invitrogen), and 1% penicillin/streptomycin. C42B4, DU145 and PC3 shATG7 no Dox/+Dox
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cells were cultured in RPMI-1640 media (Sigma, St. Louis, MO) with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin. SKOV3 cells were maintained in RPMI-1640
media with 15% FBS and 0.1% gentamicin (Gemini Bioproducts, Calabasas, CA). 800 ng/ml
of Doxycycline was used for inducing knockdown of ATG7 as described previously [107].
Cells were checked every six months and found to be mycoplasma free. The M.D. Anderson
Cancer Center Department of Systems Biology performed fingerprinting analysis to confirm
the correct identity of the cell lines. All cell lines were validated by STR DNA fingerprinting
using the AmpF_STR Identifiler kit according to manufacturer's instructions (Applied
Biosystems cat 4322288). The STR profiles were compared to known ATCC fingerprints
(ATCC.org), and to the Cell Line Integrated Molecular Authentication database (CLIMA)
version 0.1.200808 (http://bioinformatics.istge.it/clima/) (Nucleic Acids Research 37:D925D932 PMCID: PMC2686526). The STR profiles matched known DNA fingerprints.

Reagents and chemicals
IGF-1 (Catalog # 291-G1) and HGF (Catalog # 294-HGN-005) were purchased from R&D
Systems (Minneapolis, MN). Actinomycin D (Catalog # A1410) was purchased from Sigma.
Dasatinib (SPRYCEL®) was a gift from Bristol-Myers Squibb (Princeton, NJ).

miRNA Transfection:
Transient transfections were performed using Lipofectamine 2000 transfection reagent
(Invitrogen, Carlsbad, CA) for 24 hours, or 48, 72 or 96 hours for time course experiments.
Briefly, 100,000 or 200,000 cells were placed in a 6-well plate in growth media without
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antibiotics 24 hours prior to transfection. Cells were then transfected with either negative
control (N.C.) miRNA or miR-34a mimics/precursors (Ambion, Austin, TX) at a final
concentration of 30 nM, according to the manufacturer’s instructions.

RNA isolation and quantitative polymerase chain reaction (qPCR):
Total RNA was isolated from the cells by using RNeasy mini kit (Qiagen, Valencia, CA) or
using the mirVana kit (Ambion, Austin, TX) according to the manufacturer’s instructions.
For IGF-1/1R and MET activation studies, cells were serum starved 24 hours prior to IGF-1
stimulation and then 100 ng/ml of IGF-1 was added in serum free media for 0, 18 and 24
hours. To determine miR-34a and U6 (endogenous control) expression, 10 ng of total RNA
was reverse transcribed using the TaqMan miRNA reverse transcription kit (Applied
Biosystems, Foster City, CA). qPCR was performed on the Agilent 3000P system using the
human miR-34a and U6 miRNA TaqMan expression assays and the TaqMan Universal PCR
master mix (Applied Biosystems, Foster City, CA). Relative miR-34a expression was
determined using the gene comparative CT method. For gene expression analysis, 200 ng of
total RNA was reverse transcribed using ThermoScriptTM RT-PCR system for First strand
cDNA synthesis (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.
Gene expression was then determined by qPCR using the KiCq Start SYBR Green kit
(Sigma, St. Louis, MO) on the Agilent 3000P system. The primers sequences used for gene
expression SYBR Green qPCR are listed in Table 1.
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Table 1 - List of Primers and siRNA Sequences

mRNA/siRNA

Sequence ID

Primer sequence

Axl

Axl-F

5’-CGCAGGAGAAAGAGGATGTC-3’

Axl-R

5’-ACCTACTCTGGCTCCAGGATG-3’

Met-F

5’-CAGATGTGTGGTCCTTTG-3’

Met-R

5’-ATTCGGGTTGTAGGAGTCT-3’

Myc-F

5’-TCAAGAGGTGCCACGTCTCC-3’

Myc-R

5’-TCTTGGCAGCAGGATAGTCCTT-3’

ATG5-F

5’-GAGTAGGTTTGGCTTTGGTTGA-3’

ATG5-R

5’-CGTCCAAACCACACATCTCG-3’

ATG7-F

5’-GCATCCAGAAGGGGGCTATG-3’

ATG7-R

5’-AGGCTGACGGGAAGGACAT-3’

BECN1-F

5’-GCGATGGTAGTTCTGGAGGC-3’

BECN1-R

5’-AGACCCTTCCATCCCTCAGC-3’

18S-F

5’-GTAACCCGTTGAACCCCATT-3’

18S-R

5’-CCATCCAATCGGTAGTAGCG-3’

siATG5 #4-F

5’-GGUUUGGACGAAUUCCAACUUGUUU-3’

siATG5 #4-R

5’-GAUCACAAGCAACUCUGGAUGGGAU-3’

siATG5 #5-F

5’-UCUUCGAAGUGAAGCUUCCAGAAAU-3’

siATG5 #5-R

5’-CCAAUCCUGUGAGGCAGCCUCUCUA-3’

c-Met

c-Myc

ATG5

ATG7

BECN1

18s rRNA

siATG5 #4

siATG5 #5
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Enzyme-linked Immunosorbent Assay
To examine the endogenous secretion of HGF, PC3 cells were serum starved for 24 hours
and then stimulated with IGF-1 (100 ng/ml) for 0, 18 and 24 hours. Cell culture media was
harvested and analyzed in triplicate by human HGF Quantikine ELISA kit (R&D Systems),
according to the manufacturer's instructions.

Immunoblotting:
For in vitro studies of IGF-1/1R and MET activation, cells were serum starved for 24 hours
prior to stimulation with growth factors. For the IGF-1 time-course study, 100 ng/ml of IGF1 was used in serum free media for different time points. For the IGF-1 dose-dependent
study, 0, 10, 25, 50, 100 and 200 ng/ml of IGF-1 were used to stimulate the cells. For
Dasatinib studies, cells were pretreated with 100 ng/ml Dasatinib before stimulation with 100
ng/ml IGF-1 or 15 ng/ml HGF for 24 hours and 10 minutes respectively. Protein lysates were
prepared using RIPA B lysis buffer (150mM NaCl, 5mM ethylenediaminetetraacetic acid,
20mM sodium phosphate buffer, and 1% Triton X-100, pH 7.4, along with 1 tablet of
protease and phosphatase inhibitor cocktail (Roche, Indianapolis, IN). For in vivo samples,
tumor sections were cut and homogenized by magnetic beads in RIPA A lysis buffer (1%
Triton X-100, 0.% SDS, 0.5% sodium deoxycholate, 150mM NaCl, 5mM EDTA, 5mM
sodium pyrophosphate, 20mM sodium phosphate buffer, pH 7.4 along with 1 tablet of
protease and phosphatase inhibitor cocktail). Total protein lysates (15 or 30 µg) were loaded
onto an 8% or 12% polyacrylamide gel, which were then transferred to a polyvinylidene
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difluoride (PVDF) membrane and blocked with 5% milk in tris-buffered saline with Tween20. Membranes were probed with specific primary antibodies: c-Met (C12; Santa Cruz
Biotechnology, Santa Cruz, CA), Axl, cleaved caspase 3, LC3B, Beclin-1, ATG5 and ATG7,
phospho-Met Y1234/35, phospho-Met Y1349, phospho-Src Y416, Akt, phospho-Akt (S473),
MAPK, phospho-MAPK, IGF-1R, phospho-IGF-1R beta Y1135/36, ERK1/2 (Cell Signaling,
Danvers, MA), Src (EMD Millipore, Temacula, CA), c-Myc (Santa Cruz Biotechnology),
GAPDH (EMD Millipore), Vinculin (Sigma) and horseradish peroxidase-conjugated goat
anti-mouse or goat anti-rabbit secondary antibody (Bio-Rad, Hercules, CA).

Migration and invasion assay:
Migration and invasion assays were performed using migration and invasion assay inserts
(BD Biosciences, Bedford, MA). For IGF-1/1R and MET activation studies, PC3 cells
expressing the non-targeting and shMET targeting vector were serum starved for 24 hours
and then incubated with IGF-1 (100 ng/ml) for 24 hours in a culture dish. Cells were
trypsinized and for each cell type, a total of 50,000 cells were seeded on top of the inserts in
serum-free media. Media containing IGF-1 (100 ng/ml) or HGF (15 ng/ml) was used as
chemoattractant and cells were allowed to migrate for 24 hours. A total of 100, 000 cells
were seeded on top of the inserts in serum-free media 24 hours after transfection with
negative control or miR-34a mimic. Serum-free media was used as a chemoattractant and
cells were allowed to migrate or invade for 24 hours. The bottom of the inserts was then
stained with Hema-Stain (Millipore, Temacula, CA). The number of migrated or invaded
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cells for five fields was counted under a bright-field microscope and plotted as the number of
cells migrated or invaded per field. Each experiment was performed in triplicate.

Cell Proliferation assay:
For measuring cell viability, The CellTiter 96® AQueous Non-Radioactive Cell Proliferation
Assay kit (Promega, Madison, WI) was used according to the manufacturer’s instructions.
Briefly, 1000 N.C. or miR-34a transfected cells were plated in a 96-well plate for 48, 72 and
96 hours post-transfection time points of cell viability in growth media. A solution of MTS
and PMS was added to each well, incubated at 37°C 5% CO2 for 2 hours and absorbance
measured at 490 nm by EnVision® multilabel reader (Perkin Elmer, Shelton, CT). Cell
proliferation using Hoechst 33342 dye (Life Technologies) was performed according to
manufacturer’s instructions. Briefly, 2000 N.C. or miR-34a transfected cells with or without
siATG5 and siATG7, and with or without shATG7 or shBeclin-1 were seeded in a 96-well
plate and fluorescence from Hoechst dye was measured for different time points by a plate
reader and plotted as fold change relative to control (N.C. at 48h).

Flow cytometry
Propidium iodide (PI) and RNAse A (Sigma) solution was prepared according to the
manufacturer’s instructions. For cell cycle analysis, cells transfected with N.C. or miR-34a
for different time points were fixed in 70% Ethanol overnight. Fixed cells were then
resuspended in 50 µg/ml PI solution in PBS for 1 hour in the dark and then 0.2 mg/ml
DNAase-free RNase A was added and the samples incubated at 37°C 5% CO2 for 30
minutes and read on Beckman Coulter Gallios flow cytometer and analyzed on Kaluza®
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Software (Beckman Coulter). Singlet cell population was gated to exclude cell aggregates
and percentage of cells in sub-G1, G1, S and G2M phase were recorded. GFP-Certified®
Apoptosis/Necrosis detection kit (Enzo Life Sciences, Farmingdale, NY) was used for
detection of early and late-stage apoptotic as well as necrotic cells. An Annexin V-EnzoGold
(enhanced Cyanine-3) (Ex/Em: 550/570nm) conjugate was used for detection of early stage
apoptotic cells in the FL2 channel and Necrosis Detection Reagent (Red) similar to the redemitting dye 7-AAD (Ex/Em: 546/647nm), was used for late apoptosis and necrosis detection
in FL3 channel by FACS Gallios. Acridine Orange (AO) (Life Technologies) was used to
measure acidic vesicular organelles (AVOs). Cells transfected with N.C. or miR-34a for
different time points were incubated with 1ug/ml acridine orange for 30 min in the dark. In
AO-stained cells, the cytoplasm or nucleolus fluoresce bright green and dim red, whereas
acidic compartments fluoresce bright red. Green (510–530 nm) and red (>650 nm)
fluorescence emissions from 10,000 cells illuminated with blue (488 nm) excitation light
were measured with a FACS Gallios.

Transmission Electron Microscopy (TEM)
Samples fixed with a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in
0.1 M cacodylate buffer, pH 7.3 were washed in 0.1 M cacodylate buffer and treated with
0.1% Millipore-filtered buffered tannic acid, postfixed with 1% buffered osmium tetroxide
for 30 min, and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were
washed several times in water, then dehydrated in increasing concentrations of ethanol,
infiltrated, and embedded in LX-112 medium. The samples were polymerized in a 60°C oven
for 2 days. Ultrathin sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL),
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stained with uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM
1010 transmission electron microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating
voltage of 80 kV. Digital images were obtained using AMT Imaging System (Advanced
Microscopy Techniques Corp, Danvers, MA). Mr. Kenneth Dunner, Jr., performed TEM at
the TEM core (Institutional Core Grant #CA16672 High Resolution Electron Microscopy,
UTMDACC).

siRNA and shRNA transfection
Ready-to-transfect short hairpin (sh) RNA–GFP–puromycin constructs against human IGF1R (#SR302344) and Src (#SR304574) were purchased from OriGene Technologies
(Rockville, MD). An universal non-targeting negative control shRNA (#SR30004) was
provided by the manufacturer. An activated Src (Y527F) expression vector was used as
described previously (Allgayer, et al. JBC 1999). Cells were transfected using Fugene 6
reagent (Roche) or JetPRIME (Polyplus transfection, Radnor, PA) according to the
manufacturer’s instructions. Lentiviral shc-met constructs were a gift from Dr. Menashe Bar
Eli at The University of Texas MD Anderson Cancer Center. Stable clones were selected
with puromycin or sorted with GFP. Target knockdown was verified 3–4 weeks after
transfection by western blots. Two siRNA sequences each for ATG5 and ATG7 were
provided by Dr. Daniel Frigo’s laboratory. PC3 cells were transfected with 100nM of
siATG5 or siATG7 sequences using DharmaFECT1 (GE Healthcare, Lafayette, CO)
transfection reagent and 24 hours later, siATG5 or siATG7 cells were transfected with N.C.
or miR-34a using lipofectamine 2000. Lentiviral shRNA constructs for Beclin-1 were
provided by MD Anderson shRNA and ORFeome core facility. GIPZ lentiviral shBeclin-1
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(GE Healthcare) constructs were packaged in lentivirus and PC3 cells were transduced with
the concentrated vial titer with 8 μg/ml polybrene and following infection GFP positive cells
were sorted by Becton Dickinson FACS Aria II to get shBeclin-1 cells.

Immunohistochemistry (IHC) and Immunofluorescence (IF)
Paraffin embedded tumor sections were deparaffinzed and hydrated. Citrate buffer (0.1M ,
pH 6.0) was used for antigen retrieval, 3% H2O2 (Fisher Scientific, fair Lawn, NJ) in PBS
was used for endogenous peroxidase blocking and 4% fish gelatin (Electon Microscopy
Sciences, Hatfield, PA) was used for protein blocking. Met (Santa Cruz) or Axl (Thermo
Scientific) primary antibody diluted in 4% fish gelation were added to the slides overnight in
a humidity chamber at 4°C. Slides were then washed with PBS and incubated with MACH4
polymer (Bio Care Medical, Concord, CA) for 1 hour at RT. DAB (Dako, Carpinteria, CA)
chromogen was used for visualization of the signal and the nuclei were counterstained with
Hematoxylin (Sigma). Slides were then dried and mounted with Universal mount and
examined under bright field microscope. For TUNEL staining, DeadEnd colorimetric TUNEL system (Promega) was used according to manufacturer’s instructions. Briefly, FFPE
slides were deparaffinized and antigen retrieval performed with 1X Dako Antigen Retrieval
buffer. Slides were then washed with PBS, blocked with 3% H2O2 in methanol for peroxidase
blocking and in 4% fish gelatin for protein blocking. The slides were incubated with 4%
paraformaldehyde in PBS for 10 minutes at RT, washed with PBS, incubated in 0.2%
TritonX-100 in PBS for 15 min at RT, washed with PBS and incubated with Equilibration
buffer (Promega) for 10 min at RT. TUNEL incubation buffer (Promega) was added to each
slide for 1 hour at 37°C in the dark. Slides were washed in 2X SSC (Pomega) and
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counterstained with Hoechst mounting media (Life Technologies) and visualized under
fluorescence microscope. IHC and IF images were quantified by ImageJ software as
previously described [108].

In situ hybridization(ISH):
Clinical sample slides were obtained from MDACC GU Medical Oncology department.
H&E slides for each sample were provided along with unstained freshly cut slides containing
normal and prostate tumor samples. DIG-labeled probed for miR-34a and U6 endogenous
control were purchased from Exiqon (Woburn, MA) and in situ hybridization (ISH) was
performed according to manufacturer’s instructions by the Center for RNA Interference and
non-coding RNA at MD Anderson.

Animal studies:
One million PC3MM2 cells were injected sub-cutaneously in nude mice. One week after cell
injection, mice were randomized and divided into Control (N.C.) or miR-34a group. Chitosan
nanoparticles complexed with N.C. or miR-34a were prepared by the Center for RNA
Interference and non-coding RNA at MD Anderson. Nanoparticles containing N.C. or miR34a were delivered through tail vein injection, every three days for two weeks. Tumor
volume was measured by caliper instrument every three days. After two weeks of treatment,
the animals were sacrificed and tumors harvested for protein, IHC, ISH and IF. For intrafemur experiment, 1x 106 PC3MM2-LG cells labeled with luciferase and GFP were injected
in the femur of the mice. Ten days after cell injection, mice were randomized into two
groups- control and miR-34a. The chitosan nanoparticles containing N.C. or miR-34a were
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delivered via tail-vein injection every three days for three weeks. Tumor growth was
monitored through bioluminescence imaging (IVIS 200) and tumor volume was measured
before the start of treatment and at the end of treatment by magnetic resonance imaging
(MRI) (Bruker 4.7T). Micro CT imaging was performed on the Explore Locus RS preclinical in vivo scanner (GE Medical Systems, London Ontario) to visualize bone integrity at
the end of the experiment in control and miR-34a treated mice.

Statistics:
Student’s t tests and one-way ANOVA analysis of variance were used for all statistical
comparisons and a p value of <0.05 was considered statistically significant. Statistical
analyses were performed using the GraphPad Prism software.
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Chapter 3
Ligand-independent MET Activation by the IGF-1/1R Pathway
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This Chapter is based upon “Varkaris A*, Gaur S*, Parikh NU, Song JH, Dayyani F, Jin JK,
Logothetis CJ, and Gallick GE (2013) Ligand-independent Activation of MET Through IGF1/IGF-1R Signaling. Int J Cancer. 2013 Oct 1;133(7):1536-46”, with permission from
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Multiple receptor and non-receptor tyrosine kinases promote metastatic growth of prostate
cancer resulting in numerous clinical trials with small molecule inhibitors focusing on
targeting these kinases. Unfortunately, most of the clinical trials have not demonstrated
significant improvements in survival. There are multiple reasons for lack of success of these
inhibitors including involvement of multiple drivers of PCa progression as discussed in the
spiral model (see Introduction). Activation of alternative compensatory pathways or
activation of targeted kinase through non-canonical mechanism/s could also result in failure
of the inhibitors. An example of a tyrosine kinase receiving considerable attention in prostate
cancer is MET. MET is a receptor tyrosine kinase involved in embryonic development and in
adults MET facilitates tissue regeneration [34, 109]. In cancer, aberrant expression and
activation of MET can promote tumor progression by activating MAPK signaling, PI3K-Akt
axis and STAT pathway involved in cell invasion, migration, survival and proliferation [34,
41]. In the past few years, several inhibitors have targeted MET oncogene, frequently
associated with progression of solid tumors, including antibodies targeting its ligand HGF;
antibodies targeting the receptor, and small molecule inhibitors targeting the kinase activity.
While trials are ongoing, many have not been promising as exemplified in the recent failure
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of cabozatinib, a multi-kinase inhibitor with MET and VEGFR2 as the principle targets.
These failures demonstrate the necessity to understand more about the regulation of the
targeted kinase. More evidence is accruing for receptor cross talks, and ligand independent
pathways of MET activation have been reported in other cancers [41]. However, in prostate
cancer (PCa), ligand independent MET activation through other growth factor receptors has
not been investigated. In this chapter, I analyzed the ability of the IGF-1/1R pathway,
aberrantly activated in PCa [110] and in PCa bone metastasis [111], to affect MET signaling.
I hypothesized that activation of IGF-1/1R pathway leads to activation of MET and
downstream signaling components that promote tumorigenic and metastatic properties of
PCa cells. To test this hypothesis, I used PCa cell line, PC3 with high levels of MET and
IGF-1R receptor that are representative of the majority of metastatic PCa tumors [40, 112]
and examined the effects of IGF-1 stimulation on MET phosphorylation. I identified one of
the essential components required to mediate IGF-1/1R induced MET activation and further
determined the effects of MET inhibition on IGF-1-mediated migration in PC3 cells.

IGF-1 induces delayed activation of MET in PCa cell lines and xenograft tumors
Insulin-like Growth Factor (IGF) is aberrantly expressed in the microenvironment of
prostate cancer bone metastases and known to be a poor prognostic marker for PCa survival
[113]. To determine if IGF-1 affected MET phosphorylation, a time course assay was
performed in which IGF-1 was added to serum-starved cells and activation of signaling
enzymes was examined as described in Materials and Methods.
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As shown in Fig. 5, robust activation of IGF-1R was observed within 10 min, with no
activation of MET at this time. Activation of Src, Akt, and MAPK were observed with
similar kinetics to IGF-1R activation (Fig. 6), as expected. No change in protein expression
was observed for any of these signaling enzymes. In contrast to the acute activation of
signaling enzymes after IGF-1 addition, MET phosphorylation was observed beginning at
12h, reaching maximal levels at 18h, with sustained phosphorylation for at least 24h after
stimulation of PC3 cells with IGF-1 (Fig. 5). Both Y1234-1235 (tyrosine kinase domain) and
Y1349 (multi-substrate docking) sites were phosphorylated (Fig. 5), suggesting full
activation of MET occurs at these later time points. No differences in MET protein and
mRNA expression were evident by immunoblotting (Fig. 5) and qPCR (Fig. 7) respectively.
To determine if IGF-1 induction of MET phosphorylation were dose-dependent, PC3
cells were stimulated with different doses of IGF-1 ranging from 10-200 ng/ml. Under these
conditions, IGF-1R phosphorylation increased at each concentration of IGF-1 (Fig. 8). In
contrast, 25 ng/ml IGF-1 was sufficient to induce delayed phosphorylation of MET, and no
further increases in phosphorylation were observed with higher concentrations of IGF-1.
These results suggest a threshold of IGF-1R activation is sufficient to fully induce MET
phosphorylation. MET and IGF-1R protein levels remain unchanged under these conditions
(Fig. 8).
To examine the magnitude of MET phosphorylation due to IGF-1 (100ng/ml) relative
to HGF (15ng/ml), PC3 cells were stimulated with these growth factors for 10 min and 24h
and activation of IGF-1R and MET were examined. IGF-1 induced a strong delayed

43

p-IGF-1R
IGF-1R

p-METY1234-1235
p-METY1349
MET
vinculin

Figure 5 - IGF-1 induces delayed MET activation
IGF-1 was added (100 ng/ml) to PC3 cells and expression and phosphorylation of IGF-1R
and MET was examined at indicated times by immunoblotting.
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Figure 6 - IGF-1 phosphorylates downstream signaling components
IGF-1 was added (100 ng/ml) to PC3 cells and expression and phosphorylation of Akt, Src
and MAPK was examined at indicated times by immunoblotting.
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Figure 7 - Expression of MET following IGF stimulation of PC3 cells
To determine if IGF-1 increased the expression of c-met RNA, cells were treated with IGF-1
and c-met RNA was measured by qPCR 18 and 24h after IGF-1 addition. Expression was
normalized to 18s RNA expression. Data represents Mean and SEM from three independent
experiments
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Figure 8 - Dose-dependent effects of IGF-1 on receptor activation
Different concentrations of IGF-1 were added to PC3 cells at indicated times and the
magnitude of MET and IGF-1R activation was examined.
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activation of MET at 24h that was only slightly less than the rapid (10 min) MET
phosphorylation by HGF (Fig. 9), demonstrating that activation of MET by IGF-1 is likely to
activate MET functions.
Next, the effects of IGF-1 stimulation on MET activation in PC3 xenograft tumors
were examined. Briefly, 20µl of IGF-1 (100 ng/ml) were injected directly into established
PC3 xenografts and tumors were harvested 24h after injection. Immunoblotting analysis
showed that treated tumors had significantly higher levels of MET and IGF-1R
phosphorylation compared to control tumors, whereas no changes in MET and IGF-1R
expression were observed (Fig. 10). These experiments demonstrate that, IGF-1 is capable of
inducing MET phosphorylation in vitro and in vivo.

IGF-1-induced delayed MET activation is HGF-independent
HGF is the sole known ligand of MET [34, 41]. To examine if endogenous
expression/secretion of HGF could play a role in IGF-1-mediated MET activation, HGF
mRNA was examined by qPCR in PC3 cells treated with IGF-1 for time points that
correspond to minimal and maximal MET activation by IGF-1. The results show no
statistically significant differences between control and treated groups (Fig. 11A). To further
examine potential HGF expression, cell culture media from each group was harvested and
levels of HGF were determined by enzyme-linked immunoabsorbent assay (ELISA).
Secreted HGF levels were beneath the level of detection in all groups (Fig. 11B), suggesting
that PC3 cells do not secrete HGF before or after IGF-1 addition.
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Figure 9 - Comparison of HGF and IGF induced MET activation
IGF-1 (100 ng/ml) and HGF (15 ng/ml) were added to PC3 cells at indicated times and
activation of MET and IGF-1R was examined.
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Figure 10 - IGF-1 induces MET activation in PC3 tumor xenografts
PC3 tumors were grown subcutaneously until they reached a volume of 500 mm3. IGF-1
(100 ng/ml, 20µl total volume) was injected into the tumor. Tumors were harvested 24h later,
and expression and phosphorylation of IGF-1R and MET was examined.
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Figure 11 - Expression of HGF after IGF-1 addition
Total RNA was isolated from PC3 cells 24h after IGF-1 addition (100ng/ml), and HGF
expression was examined by qPCR (A) and ELISA (B). Data represent Mean and SEM from
three independent experiments.
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IGF-1-mediated MET phosphorylation requires IGF-1R activation
To examine whether IGF-1R activation were required for “lateral” MET
phosphorylation, we generated a PC3 cell line in which IGF-1R was stably knocked down by
expression of an shIGF-1R construct as described in Materials and Methods. Expression of
IGF-1R was reduced >90% (Fig. 12, lane 5 and 6). When the shIGF-1R cells were stimulated
with IGF-1, delayed MET phosphorylation was abolished; demonstrating activation of IGF1R is required for inducing MET phosphorylation (Fig. 12, lane 5 and 6).

Src activation is essential for IGF-1-induced delayed MET activation
In a study of Dulak et al. tyrosine kinase, Src, was shown to be an essential mediator
of lateral activation of MET by EGFR [43]. To examine potential roles of Src family kinases
in delayed MET activation by IGF-1R, I first used the multi-targeted SFK inhibitor,
dasatinib. PC3 cells were pretreated with 100 nM of dasatinib for 2h before stimulating with
IGF-1 and HGF for 24h and 10 min respectively. Under these conditions, IGF-1-induced
delayed MET activation was abolished, suggesting that activation of a Src family kinase may
be required for delayed MET phosphorylation (Fig 13). In contrast, dasatinib had little effect
on HGF-induced direct MET activation (Fig 13). Decreases in MET activation were
observed in dasatinib only treated cells (Fig 13, lane 2) suggest that dasatinib might have a
small effect on MET phosphorylation (dasatinib is a multi-kinase inhibitor). To determine if
activation of Src (as opposed to other Src family kinases) were essential to delayed MET
phosphorylation by IGF-1, I stably expressed a shRNA for Src in PC3 cells. As shown in
Fig. 12, greater than 90% knockdown of Src was observed (Fig 12, lane 3 and 4).
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Figure 12 - Effects of IGF-1 and Src knockdown on IGF-1-mediated MET activation
IGF-1 (100ng/ml) was added to non-targeting cells or cells with stable knockdown of IGF1R (shIGF-1R) or Src (shSrc), following which MET phosphorylation was examined.
Vinculin was used as a loading control.
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Figure 13 - Effects of Dasatinib on IGF-1-mediated MET activation
PC3 cells were pre-treated with100nM of Dasatinib for 2h after which they were stimulated
with IGF-1 (100 ng/ml) for 24h or HGF (15 ng/ml) for 10min. MET and Src phosphorylation
were then examined.
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As with non-targeting clones, IGF-1 was added and MET phosphorylation was examined 18h
later. In PC3 cells expressing a non-targeting shRNA, MET was phosphorylated under these
conditions (Fig. 12, lane 1 and 2). In contrast, the shSrc cells were unable to induce delayed
MET activation, with expression of MET unchanged, suggesting Src is required for IGF-1
induced MET activation (Fig. 12, lane 3 and 4). To further determine whether Src activation
was required for IGF-1-induced MET phosphorylation, I transfected PC3 ShSrc cells with a
plasmid harboring a Src mutant (Y527F) that leads to constitutive Src activation and then
stimulated the cells with IGF-1 for 24h. Expression of an activated Src led to MET
phosphorylation in the presence or absence of IGF-1 (Fig. 14), suggesting Src activation
alone is necessary and sufficient to trigger the cascade leading to MET activation.

Inhibition of transcription abolishes IGF-1R-mediated MET phosphorylation
Since, MET phosphorylation occurs much later than activation of other signaling
intermediates (Src, Akt, MAPK), I determined if transcription were required for IGF-1R to
MET cross talk. For these experiments, PC3 cells were treated with the pan-transcription
inhibitor, actinomycin D, alone or in combination with IGF-1 for time points corresponding
to the maximal IGF-1-induced MET activation. Lack of synthesis of the precursor of MET
(upper band, Fig. 15) indicates actinomycin D blocked de novo c-met mRNA synthesis.
Processed MET (lower band) was still present, as expected. These results suggest no further
transcription of MET occurred under these conditions. Successful inhibition of transcription
abolished IGF-1-induced MET activation (Fig. 15), whereas IGF-1-induced IGF-1R
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Figure 14 - Src activation is required for IGF-1-mediated MET activation
PC3 cells with stable knockdown on Src (PC3shSrc) were transfected with a constitutively
active SRC (Src Y527F) mutant for 48h followed by stimulation with IGF-1 (100 ng/ml) for
24h. Phosphorylation of MET (pY1349), IGF-1R and Src were then examined after 24h of
IGF-1 stimulation.
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Figure 15 - Inhibition of transcription abolishes IGF-1R-mediated MET
phosphorylation
Actinomycin D (0.01 mg/ml) was added to cells to inhibit transcription. IGF-1 was then
added (100 ng/ml) and IGF-1R and MET phosphorylation was examined 18h (lanes 3 and 5)
and 24h (lanes 4 and 6) later.
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activation (which occurs within 10 min and does not require transcription) was unaffected.
These findings indicate that transcription is essential for IGF-1-induced MET activation.

MET inhibition abrogates IGF-1-induced migration
Upon activation, MET signaling plays a critical role in prostate cancer cell invasive
growth (scattering, migration, invasion and metastasis) [34, 35]. I therefore determined if
IGF-1-induced MET activation affected cellular migration. These experiments were
performed with a PC3 cell line stably expressing shRNA to c-met, constructed as described
in Materials and Methods. Expression of the c-met-specific shRNA resulted in >95%
reduction of MET protein expression compared to PC3 cells expressing a non-targeting
shRNA (Fig.16A). A migration assay was then performed with cells expressing MET or in
cells in which MET had been knocked down and migrated cells were counted. Under these
conditions, IGF-1 induced a 2.5 fold increase in migration in cells expressing a non-targeting
vector relative to non-stimulated cells (p<0.0001), (Fig. 16B), in agreement with data
previously published from other groups [114]. In contrast, in cells in which MET was
decreased by expression of shRNA, no induction of migration by IGF-1 was observed (Fig.
16B). In cells not stimulated with IGF-1 but in which HGF was used as a chemoattractant, a
3 fold increase in migration was observed (p<0.0001), consistent with the role of activated
MET in promoting migration (Fig. 16C). These results suggest that IGF-1-mediated
increased migration is mediated by MET activation. Overall, the experiments confirm that
delayed phosphorylation of MET leads to a functional MET capable of inducing one of its
principal roles, migration.
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Figure 16 - Role of MET in IGF-1-mediated migration of PC3 cells
Stable knockdown of MET expression by achieved by using an shRNA construct (A). Effects
of IGF-1 (B) and HGF (C) on migration of PC3 cells were determined. 5x104 Cells were
plated on top of a Boyden Chamber as described in Materials and Methods. IGF-1
(100ng/ml) (B) or HGF (15ng/ml) (C) were used as a chemoattractant. Migration was
compared in shc-Met knockdown cells and respective controls. Data represent Mean and
SEM from three independent experiments; *p<0.0001 (one-way ANOVA analysis of
variance).
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MET is Activated in Multiple Cell Lines Expressing IGF-1R
I next examined whether IGF-1-induced MET activation occurred in another
commonly used metastatic prostate cancer cell line, DU145, which expresses both IGF-1R
and MET. As before, analysis of MET expression and phosphorylation was performed after
0h, 18h and 24h of IGF-1 treatment. Kinetics of MET phosphorylation in these DU145 cells
were similar to that of PC3 (Fig. 17). Finally, as IGF-1 is abundantly expressed in the serum
of patients with other types of cancer, I examined the effect of IGF-1 on HT29 colon cancer
cells and A549 lung cancer cells, both of which express IGF-1R and MET to differing levels.
Delayed phosphorylation of MET was observed in both of these cell lines (Fig 18A, B),
though not to the extent of the prostate cancer cells that express higher basal levels of MET.
These results suggest that delayed activation of MET is likely a common cross talk pathway
in cells expressing both IGF-1R and MET, and this process may contribute to phenotypes
associated with MET activation in multiple types of cancer.

Integrins do not mediate cross talk between IGF-1R and MET
While several mechanisms might contribute to non-ligand mediated MET
phosphorylation, integrins are an attractive possibility as increased integrin clustering and
activation not only leads to MET activation, but also to that of Src and downstream pathways
[115, 116]. To examine this possibility, PC3 cells with stable expression of an Shβ1integrin
were stimulated with IGF-1. MET was phosphorylated in both non-targeting and shβ1
integrin knock down cells, suggesting that β1 integrin is not required for delayed MET
activation (Fig 19).
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Figure 17 - Effects of IGF-1 on MET phosphorylation in DU145 cells
DU145 (Prostate Cancer cells) expressing both IGF-1R and MET were stimulated with IGF1 (100 ng/ml) as described in Materials and Methods. Expression and phosphorylation of
MET and IGF-1R examined 18 and 24h later.
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Figure 18 - Effects of IGF-1 on MET phosphorylation in different cancer cell lines
HT29 (Colon Cancer) (A) and A549 (Lung Cancer) (B) cell lines, expressing both IGF-1R
and MET were stimulated with IGF-1 and expression and phosphorylation of MET and IGF1R was examined 18h and 24h later.
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Figure 19 - Effect of integrin β1 knockdown on MET phosphorylation
IGF-1 (100 ng/ml) was added to non-targeting cells (PC3Shcontrol) or cells that had stable
knock down of integrin β1 (PC3ShIntβ1) and MET phosphorylation (and expression) was
determined 24hr later.
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Discussion
In this chapter, I demonstrate for the first time that in tumor cell lines in which both
IGF-1R and MET are expressed, IGF-1R activation is sufficient to lead to a delayed
phosphorylation of MET in a process that is independent of MET ligand, HGF and without
increasing MET expression. Phosphorylation of MET occurs at each tyrosine examined,
suggesting that MET becomes fully activated, in accord with the results demonstrating
requirement of MET for IGF-1-mediated migration. IGF-1R and Src are required to induce
delayed MET phosphorylation in a mechanism dependent on transcription since inhibiting
transcription abolished IGF-1-induced MET activation. The transcriptional mediator/s
involved in this pathway remains to be identified. It is possible that Src activation facilitates
the transcription of an unknown factor by enhancing activity of a transcriptional factor and
the transcription of this unknown factor then leads to MET activation. The results from this
chapter demonstrate an alternate mechanism of MET activation suggesting that MET reactivation through receptor cross talk might be one of the reasons for failure of MET
inhibitors in clinical trials. These findings suggest utilization of another strategy to inhibit
aberrantly expressed tyrosine kinases in cancer by inhibiting the protein expression of these
kinases. One such strategy is through miRNA-mediated gene regulation and inhibition of
multiple targets implicated in cancer progression, which I further examined in the next
chapters.
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Chapter 4
Effects of miR-34a Overexpression on Expression of Targets and
Properties Associated with Metastasis in vitro
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MicroRNA-mediated gene regulation and development of miRNA-based therapies for
therapeutics is one approach to inhibit expression of multiple oncogenic proteins and thereby
inhibit several cancer-promoting pathways. In prostate cancer, increased expression of
receptor tyrosine kinases MET and Axl is reported with disease progression, further
enhancing tumor growth at the metastatic site, principally the bone [40, 48]. Both of these
receptor tyrosine kinases promote cancer cell survival, proliferation, migration and invasion
[4, 35, 46, 47, 117]. Aberrant expression of transcription factor c-Myc is reported in prostate
cancer and evidence from transgenic models implicates c-Myc in driving development of
invasive prostatic carcinomas [25, 26, 51]. Myc is a proto-oncogene that regulates
transcription of genes involved in promoting cancer cell growth and proliferation [50]. As
discussed in Introduction (Chapter 1), targeting multiple gene products is important to inhibit
activation of disparate signaling pathways that promote cancer progression. MicroRNA-34a
is a tumor suppressive miRNA that targets and inhibits many of the genes involved in cancer
development and metastasis. Importantly, miR-34a inhibits protein expression of MET, Axl
and c-Myc in several cancers [45, 53, 75, 83, 84]. I therefore hypothesized that decreased
miR-34a expression leads to upregulation of targets that promote PCa progression, and in
vitro overexpression of miR-34a will inhibit tumor-promoting properties. To test this
hypothesis, I determined miR-34a expression in prostate cancer cell lines and studied the
effects of modulating miR-34a expression on biological properties associated with increased
metastatic potential.
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Expression of miR-34 family members in PCa cell lines
To examine the role of miR-34 family in prostate cancer, I used qPCR to quantify
relative expression of miR-34 family members: miR-34a, miR-34b and miR-34c in PCa cell
lines. I compared the expression of these miRs in LNCaP cells (which do not metastasize in
immunocompromised mice) and C42B4 (with low metastatic potential) cells to more
aggressive PC3 (high metastatic potential) and PC3MM2 (selected for increased metastatic
potential relative to parental PC3). Expression of miR-34b (Fig. 20A) and miR-34c (Fig.
20B) was very low in all the tested PCa cell lines. In contrast, expression of miR-34a was
high in cells of low metastatic potential and decreased substantially in cells of high metastatic
potential (Fig. 20C). Specifically, expression of miR-34a was decreased by 8-fold in PC3
and by 12-fold in PC3MM2 compared to C42B4 and LNCaP cells (Fig. 20). This result
demonstrates that miR-34a expression is inversely proportional to aggressiveness and
metastatic potential of PCa cell lines, in agreement with a potential role as a tumor
suppressor in PCa. Among the miR-34 family, I thus chose miR-34a to determine if it
regulated targets critical to PCa progression, and biological properties associated with
increased metastasis potential in vitro.

miR-34a targets are overexpressed in aggressive PCa cells
To examine whether miR-34a overexpression could regulate targets associated with
increased metastatic potential of PCa cell lines, I determined the expression of MET, Axl and
c-Myc in LNCap, C42B4, PC3 and PC3MM2 cells. These targets are increased in mRNA
(Fig. 21A-C) and protein expression (Fig. 21D) in PC3MM2 and PC3 cells relative to
LNCaP and C42B4 cells, in accord with the different metastatic potentials described above.
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Figure 20 – Expression of miR-34 family members in PCa cell lines
Total RNA was isolated from cell lines and qPCR performed for miR-34b (A), miR-34c (B)
and miR-34a (C) using TaqMan assays as described in Materials and Methods. U6 was used
as endogenous control and ΔCt method was used for quantification. Data represents Mean
and SD from three independent experiments.
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Figure 21 - miR-34a targets are overexpressed in aggressive PCa cell lines
Total RNA and protein was isolated from cell lines and mRNA expression of c-Met (A), cMyc (B) and Axl (C) was measured using SYBR Green qPCR using 18S RNA expression as
endogenous control. Data represents Mean and SD from three independent experiments.
Protein expression was measured by immunoblotting (D). GAPDH was used as loading
control.
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To determine if miR-34a regulated expression of these targets, I overexpressed miR-34a by
transiently transfecting low miR-34a expressing PC3 and PC3MM2 cells with negative
control miRNA (N.C.) or miRNA-34a (miR-34a) mimics as described in Materials and
Methods. Overexpression of miR-34a (Fig. 22A) led to decreased expression of protein (Fig.
22B) as well as mRNA (Fig. 23) of MET, Axl, and c-Myc in PC3 and PC3MM2 cells. These
data thus demonstrate that miR-34a overexpression simultaneously inhibits the expression of
these targets in PCa cell models commonly used to study tumor progression and metastasis.

Effects of miR-34a overexpression on properties associated with aggressiveness and
metastatic potential of PC3 cell line
I next determined the biological effects of miR-34a overexpression in PC3 cells. Cells
transfected with N.C. or miR-34a for 24h were seeded on Boyden chamber inserts as
described in Materials and Methods. Overexpression of miR-34a significantly decreased the
ability of PC3 cells to migrate by 50% (Fig. 24A) and the ability to invade by 75% (Fig.
24B). I then determined the effects of miR-34a on cell proliferation by using a MTS assay.
Cells after 24h of N.C. or miR-34a were counted and seeded in 96-well plates. Absorbance at
490nm was measured for different time points by EnVision® multilabel plate reader.
Overexpression of miR-34a decreased cell proliferation by 1.6-fold at 72 hours and by 2-fold
at 96 hours compared to N.C. (Fig. 25A). I next performed cell cycle analysis using
propidium iodide (PI) at various times after N.C. or miR-34a transfection in PC3 cells. A 4fold decrease in S-phase was observed beginning at 48 hour, which is maintained through 96
hours post-transfection (Fig. 25B). After 72 hours, the sub- G1 phase increased by 1.5 fold in
miR-34a overexpressing cells, reaching a maximum of 2-fold at 96 hours relative to N.C.
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Figure 22 - Overexpression of miR-34a decreases protein expression of its targets
miR-34a expression after transient transfection was measured and plotted by using the
TaqMan assay for miR-34a and U6 as a control (A). Protein expression of miR-34a targets
(MET, Axl and c-MYC) after N.C. or miR-34a transfection is shown by immunoblotting (B).
GAPDH was used as loading control.
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Figure 23 - Overexpression of miR-34a decreases mRNA expression of its targets
mRNA expression of c-Met (A), Axl (B) and c-Myc (C) after miR-34a overexpression are
quantified using SYBR Green qPCR in PC3 and PC3MM2 cell lines. * denotes p value <0.05
as measured by student’s t test.
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Figure 24 - Effects of miR-34a overexpression on migration and invasion abilities of
PC3 cells
Migratory (A) and invasive (B) ability of PC3 was measured after N.C. or miR-34a
transfection by using Boyden chamber inserts in serum free media. Cells that migrated or
invaded the matrigel layer were stained, quantified and plotted. * denotes p value <0.05 as
measured by student’s t test.
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Figure 25 - Effects of miR-34a overexpression on cell proliferation and cell cycle
MTS assay was performed on N.C. or miR-34a transfected for different time points and mean
absorbance at 490 nm from triplicate wells was plotted (A). Propidium iodide staining was
used for cell cycle analysis and the different cell cycle phases from N.C. or miR-34a
transfected cells for 48h, 72h and 96h were analyzed and quantified (B). * denotes p value
<0.05 as measured by student’s t test.
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transfected cells (Fig. 25B). These results demonstrate that overexpression of miR-34a both
decreased cell proliferation and increased cell death. To determine what type(s) of cell death
were occurring, I used a GFP-Certified® Apoptosis/Necrosis detection kit as described in the
Materials and Methods. An increase in early (AnnVEnzoGold+/7AAD-) and late apoptotic
(AnnVEnzoGold+/7AAD+) cell populations were observed at 72 and 96 hours post miR-34a
transfection compared to N.C. transfected cells (Fig. 26A). In addition, an increase in cleaved
caspase 3 were observed with miR-34a overexpression at 72 and 96 hours (Fig. 26B)
demonstrating that apoptosis occurred at these time points.

These results thus demonstrate that overexpression of miR-34a decreases properties
associated with metastasis by inducing apoptosis, decreasing cell proliferation, cell migration
and invasion, in accord with miR-34a being a tumor suppressive miRNA. Overexpression of
miR-34a decreases both mRNA and protein expression of MET, Axl and c-Myc, targets
implicated in prostate cancer progression further corroborating the application of miR-34a
delivery as a treatment strategy for metastatic prostate cancer which I tested in next the
chapter.
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Figure 26 - miR-34a overexpression increases apoptosis in PC3 cells
Apoptotic cells and necrotic cells in N.C. or miR-34a transfected cells for different time
points were analyzed and quantified by Gallios FACS using a GFP-Certified®
Apoptosis/Necrosis detection kit as described in Materials and Methods (A). Protein
expression of Cleaved Caspase 3 is visualized by immunoblotting after time course
transfection with N.C. or miR-34a (B).
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Chapter 5
Chitosan Nanoparticle Mediated Delivery of miR-34a Decreases Prostate
Tumor Growth in in vivo Models

77

Most deaths of prostate cancer patients are due to development of bone metastasis. Currently
available therapies have severe toxicities and limited success in treatment of bone metastasis.
It is thus essential to develop alternate treatment strategies such as miRNA replacement
therapy to deliver tumor suppressive miRNA/s that will inhibit multiple genes that contribute
to growth to cancer progression and growth at metastatic site. Previous studies have
demonstrated that delivery of tumor suppressive miRNAs in different in vivo cancer models
is effective in inhibiting primary tumor growth and experimental metastasis [118]. Delivery
of miR-34a has been shown to be effective in inhibiting growth of orthotopic prostate tumor
and lung metastasis [84]. However, it is not known whether miR-34a delivery will decrease
prostate tumor growth in the bone, the principal site of PCa metastasis. In this chapter, I
determined whether miR-34a could be delivered in in vivo model systems, inhibit its known
targets and decrease tumor growth. I used PC3MM2-LG cells as they have been shown
previously to grow in the bone. I used chitosan nanoparticles, currently in development for
clinical applications due to their favorable biocompatible properties making them an
attractive delivery vehicle [70, 119]. Previous studies demonstrated effective siRNA and
miRNA delivery using chitosan nanoparticles in in vivo models without severe toxicities [70,
73] further corroborating their clinical application.

miR-34a delivery by chitosan nanoparticles inhibits prostate tumor growth in subcutaneous model
I first tested whether delivery of miR-34a in chitosan nanoparticles would lead to
downregulation of the targets I examined, MET, Axl and c-Myc in in vivo model system. For
these studies, tumors were grown subcutaneously as described in Materials and Methods and
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miR-34a was delivered to these tumors systemically encapsulated in chitosan, a cationic,
biodegradable, naturally occurring polymer [70, 119]. I first determined whether miR-34a in
chitosan nanoparticles could be delivered systemically and whether its delivery inhibited
known targets and decreased tumor growth in a sub-cutaneous model. PC3MM2 cells were
injected in nude mice and one week after tumor injection, intra-venous (i.v.) treatment was
started to deliver miRNAs encapsulated in chitosan (CH) nanoparticles for control miR or
miR-34a and continued for two weeks. Robust expression of miR-34a expression was
observed in tumors that received miR-34a-CH nanoparticles as visualized by ISH (Fig. 27A).
Next, I examined the expression of MET, Axl and c-Myc. Expression of these proteins was
decreased as determined by IHC (Fig. 27A, B) and immunoblotting (Fig. 27C) in miR-34a
treated tumors. Tumor volume measurements demonstrated that miR-34a delivery decreased
tumor growth compared to control tumors (Fig. 28). The delivery of miR-34a also induced
apoptosis as measured by an increase in TUNEL positive cells in miR-34a treated tumors
(Fig. 29) compared to control tumors. This result suggests that miR-34a delivery decreases
tumor growth by inducing apoptosis.

Effects of miR34a delivery on growth of PCa cells in the bone
The main question I wished to address was whether systemic miR-34a delivery
affected tumor growth in an intra-femur model to represent PCa bone metastasis, as no
effective therapies for bone metastases currently exist. First, to determine whether chitosan
could deliver small RNAs to the bone, I used Cy5.5-labeled siRNA to detect Cy5.5
fluorescent signal from the femurs by ex vivo imaging. PC3MM2-LG cells were
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Figure 27 - Chitosan mediated delivery of miR-34a decreases target expression
FFPE slides were stained with H&E and in situ hybridization was performed for miR-34a
and endogenous control U6 along with IHC for MET and Axl (A). The mean intensities for
10 areas from each slide at 10x magnification was quantified using color deconvulation H
DAB macros in ImageJ software or mean intensities were measured with NIS Elements
software (B). Protein expression of MET, Axl and c-Myc from control and miR-34a treated
tumors were analyzed by immunoblotting (C) * denotes p value <0.05 as measured by
student’s t test.
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Figure 28 - Systemic miR-34a delivery by chitosan nanoparticles decreases subcutaneous prostate tumor growth
Tumor volume of sub-cutaneous PC3MM2 tumors was measured by caliper and plotted for
control and miR-34a treated group. * denotes p value <0.05 as measured by student’s t test.
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Figure 29 - miR-34a delivery induces apoptosis in sub-cutaneous model
TUNEL staining was performed on tumors as described in Materials and Methods. TUNEL
positive (Green) cells were quantified using ImageJ software from 10 fields per tumor and
the mean and standard deviation is plotted and a representative image is shown for control
and miR-34a treated tumor for nuclear DAPI (blue) and CD31 (red) staining. * denotes p
value <0.05 as measured by student’s t test.
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injected in the femur of nude mice and ten days after tumor injection, unlabeled control or
Cy5.5-siRNA in chitosan nanoparticles were delivered by tail-vein administration. Animals
were sacrificed three days after delivery and IVIS 200 visualized fluorescent intensities from
harvested legs. Fluorescence imaging demonstrates an increase in Cy5.5-siRNA signal
intensity in the femur with tumor than in the femur without tumor (Fig. 30) suggesting that
tumor retains the siRNA delivered by chitosan nanoparticle.
I next determined the effect of miR-34a delivery on established tumors in the femur
to best mimic treatment of men presenting with bone metastasis. For this experiment,
PC3MM2-LG cells were injected in the femur of nude mice and bioluminescent activity and
MRI was used to measure tumor growth and volume. After ten days, when tumors were
evident in the femurs (as measured by MRI), mice were randomized and treated with either
control-miR-CH or miR-34a-CH nanoparticles every three days for three weeks through i.v.
administration. The delivery of miR-34a decreased growth of established prostate tumors in
the bone compared to control (Fig. 31) as measured by bioluminescent activity of PC3MM2LG cells. This finding is supported by decreased tumor volume in miR-34a treated group
compared to control group as measured by MRI (Fig. 32). PC3MM2 cells cause lytic
reaction in the bone and miR-34a delivery preserved bone integrity as visualized by micro
CT analysis (Fig. 33). This study thus demonstrates that miR-34a can be delivered to the
bone and its delivery decreases tumor growth as well as preserves bone integrity in an intrafemur mouse model representative of PCa bone metastasis.
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Figure 30 - Chitosan delivers Cy5.5-siRNA to the femur
Control or Cy5.5-labeled siRNAs were encapsulated in chitosan nanoparticles and injected
i.v. and fluorescent imaging performed as describe in Materials and Methods. Both Femurs
(with and without tumor growing) were harvested and subjected to ex vivo imaging. Red
arrow indicates fluorescent signal from Cy5.5-siRNA.
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Figure 31 - Systemic miR-34a delivery by chitosan nanoparticles decreases prostate
tumor growth in the bone
Bioluminescent activity from the femur was measured using IVIS 200 and plotted for control
and miR-34a treatment groups (n=5) and *denotes p<0.05 as measured by student’s t test.
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Figure 32 - miR-34a delivery decreases prostate tumor volume in the bone
Tumor volume was measured before and after miR-34a delivery by MRI and plotted (top).
Representative images from the MRIs of the femurs (red dotted line) for control-CH and
miR-34a-CH treated mice are shown (bottom). *denotes p<0.05 as measured by student’s t
test.
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Figure 33 - miR-34a delivery preserves bone integrity
micro CT images for control and miR-34a treated mice are shown and red arrow indicates
bone lesions.

87

Discussion
Results presented in this chapter providence evidence for miR-34a delivery as a
strategy to decrease growth of established tumors in the bone with preservation of bone
integrity. The delivery of miR-34a in an intra-femoral model demonstrates stronger tumor
inhibition than the sub-cutaneous model. Krzeszinski et al. recently demonstrated that miR34a delivery decreased tumor growth primarily by inhibiting osteoclast activity in breast
cancer and melanoma mouse model [74]. Liu et al. demonstrated that miR-34a delivery
decreases prostate tumor growth in an orthotopic model [84]. These findings combined with
my previous results demonstrating anti-tumor effects of miR-34a suggest that miR-34a could
be affecting both tumor as well as the microenvironment and further corroborates miR-34a
delivery strategy for treatment of primary and metastatic prostate cancer. The effects of miR34a on inducing apoptosis in vivo are much more profound than inducing apoptosis in vitro,
implicating that additional cell death mechanism/s might be mediated by miR-34a.
Autophagy, a cellular stress induced survival mechanism has complex role in cancer
with several studies reporting autophagy-mediated tumor suppression and demonstrating
involvement of autophagy in promoting cancer cell death [96, 97, 99, 120, 121]. Thus, with
the goal to address whether autophagy mediates cell death in vitro, in the next chapter I
determined the effects of miR-34a overexpression on inducing autophagy in cell line models.
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Chapter 6
Overexpression of miR-34a Induces Autophagy
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Autophagy is a process important in maintaining cellular homeostasis by removing damaged
organelles and proteins from the cell [92]. In cancer, autophagy is induced in response to
stress conditions for example, nutrient and growth factor starvation, hypoxia and
chemotherapy [92, 96]. Autophagy can be tumor promoting by enhancing cancer cell
survival; however, many reports suggest tumor suppressive role of autophagy by regulating
various cell death pathways including apoptosis [121]. There is evidence of cross talk
between the apoptosis and autophagy pathways and both processes have been reported to
occur simultaneously in cancer cells [121]. Downregulation of MET or Axl, two of miR-34a
targets studied in this dissertation have both been shown to induce both apoptosis and
autophagy in several cell lines [105, 106]. My observations of cell morphology with bright
field microscopy indicated changes in cell size and structure occurred over time following
miR-34a overexpression in PC3 cells (Fig. 34). Specifically, cells overexpressing miR-34a
appeared are more flattened and larger than N.C. transfected cells starting at 48 hours. By 96
hours, miR-34a overexpressing cells had a morphology characteristic of cells undergoing
autophagy. Since, miR-34a downregulates both MET and Axl, in this chapter, I examined
whether miR-34a overexpression induces autophagy in addition to apoptosis first in PCa cell
lines, and then determined whether miR-34a overexpression caused similar effects in cell
lines derived from other tumor types.
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Figure 34 - miR-34a overexpression alters PC3 cell morphology
PC3 cells transfected with N.C. or miR-34a at different time points were imaged by bright
field microscopy at 10X magnification using Nikon camera and representative images are
shown.
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Overexpression of miR-34a induces autophagy in cancer cell lines
Several markers indicative of autophagic process were examined in this chapter. I
first analyzed Beclin-1 expression in cells transfected with N.C. or miR-34a, as it is involved
in vesicle nucleation and autophagosome formation [122]. An increase in Beclin-1 protein
but not mRNA expression (not shown) was observed at 48 hours in miR-34a cells, and
continues throughout the time course examined (Fig. 35A).
Next, as a classic marker of autophagy, conversion of LC3I to LC3II, involved in
autophagosome maturation [123, 124], was examined. LC3II expression was increased in
miR-34a-overexpressing cells 48 hours after transfection and is maintained at 72, and 96
hours (Fig. 35A). Next, to quantitatively measure the presence of acidic vesicular organelles
(AVOs), cells transfected with N.C. or miR-34a for increasing times were stained with
acridine orange and analyzed by flow cytometry as described in Materials and Methods. An
increase in acridine orange-positive cells (AO+) was observed in miR-34a overexpressing
cells at 48 hours with further increases noted at 72 and 96 hours (Fig. 35B), a time frame
similar to that observed for LC3II increase. To determine whether autophagic structures were
present in miR-34a overexpressing cells, transmission electron microscopy (TEM) was
performed. As shown in Fig. 36, miR-34a led to an abundant accumulation of
autophagosome (AP)-like structures (black arrows) as well as autolysosome (AL)-like
structures (red arrows) that are not observed in N.C. cells. This result confirms the presence
and accumulation of autophagic structures in miR-34a-induced autophagy in PC3 cells.
These data demonstrate that miR-34a overexpression increases molecular markers associated
with initiation, maturation and progression of autophagy.
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Figure 35 - miR-34a overexpression induces autophagy in PC3 cells
Western blots for LC3B, Beclin-1 and GAPDH for N.C. and miR-34a transfected cells for
different time points are shown (A). Acridine orange staining for N.C. or miR-34a
transfected cells for different time points was analyzed by Gallios FACS and quantified (B).
*denotes p<0.05 as measured by student’s t test.
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Figure 36 - TEM in miR-34a overexpressing PC3 cells
TEM images at 2500X and 25000X magnification were captured for N.C. and miR-34a
transfected PC3 cells at 72h. Black arrows indicate autophagosome (AP)-like structures and
red arrows indicate autolysosome (AL)-like structures.
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Overexpression of miR-34a induces autophagy in multiple cell lines
I next examined whether miR-34a induced autophagy in other PCa cell lines. The
overexpression of miR-34a increased Beclin-1 expression in PC3MM2 cells and LC3II
expression in both PC3MM2 and C42B4 cells (Fig. 37A). These increases are similar to
those observed in PC3 cells. An increase in acridine orange-positive cells is observed in both
PC3MM2 and C42B4 cells (Fig. 37B) with miR-34a overexpression at 72 hours posttransfection. To study whether miR-34a-mediated autophagy occurs in other cell types, I
transfected HepG2 (a hepatocellular carcinoma cell line), A549 (a lung cancer cell line),
MDA MB 231 (a breast cancer cell line) and SKOV3 (an ovarian cancer cell line) with N.C.
or miR-34a and measured Beclin-1 and LC3II expression. Overexpression of miR-34a in
these cell lines increased LC3BII and often Beclin-1 levels at the 72-hour time point, similar
to what is observed in prostate cell lines (Fig. 38A). Overexpression of miR-34a induced cell
morphology changes in A549 and HepG2 that are similar to the changes observed in PC3
cells with increase in cell size and flattened appearance (Fig. 38B). These results suggest that
miR-34a induces autophagy in PCa and other cancer cell lines examined in this study.
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Figure 37 - miR-34a induces autophagy in prostate cancer cell lines
Western blots for Beclin-1, LC3B and GAPDH after 72h transfection with N.C. or miR-34a
is shown (A). Acridine orange staining quantification (above) and graphs (below) are shown
at 72h after N.C. or miR-34a transfection (B) in PCa cell lines (PC3, PC3MM2, and C42B4).
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Figure 38 - miR-34a induces autophagy in other cancer cell lines
Western blots for Beclin-1, LC3B and GAPDH after 72h transfection with N.C. or miR-34a
are shown for cancer cell lines (HepG2, A549, MDA MB231 and SKOV3) (A). Bright field
images at 10x magnification are shown for A549 and HepG2 at 72h post-transfection with
N.C. or miR-34a (B)
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Discussion
The data presented in this chapter suggest that overexpression of miR-34a induces
autophagy with increase in LC3II and Beclin-1 expression and increase in acidic vesicular
organelles (AVOs) as well as increase in autophagic structures (APs and ALs).
Overexpression of miR-34a induces autophagy in all cancer cell types examined in this
chapter, suggesting the effects of miR-34a overexpression are not prostate-specific. These
results are contrary to findings of Liu et al. that suggest that miR-34a inhibits autophagy in
retinoblastoma cell line by inhibiting HMGB1 under serum starvation and chemotherapy
conditions [91]. They did not test whether miR-34a inhibits HMGB1 and autophagy in other
cell types. Expression of HMGB1 at mRNA levels was not affected by miR-34a
overexpression in PC3 cell line (data not shown), suggesting that HMGB1 was not mediating
miR-34a induced autophagy in this system. Downregulation of MET or Axl, miR-34a targets
previously reported to induce autophagy along with apoptosis [105, 106] could be mediating
miR-34a-induced autophagy observed in this chapter. Also, the levels of miR-34a expression,
along with different cellular stress conditions could be responsible for autophagy inhibition
or initiation, since loss of miR-34a-HMGB1 pathway was reported to inhibit autophagy and
increase ROS production under chemotherapy [91]. In this dissertation, miR-34a expression
is increased several folds and autophagy occurs under complete growth medium conditions
which could explain the difference in the result with previously published report. The
molecular intermediates required for miR-34a-mediated autophagy remains to be identified.
In the next chapter, I focused on determining whether miR-34a induces canonical autophagy
by studying the involvement of essential autophagy genes.
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Chapter 7
Overexpression of miR-34a Induces a Non-Canonical Form of Autophagy
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Autophagy is now a general term for defined events that often occur in response to cellular
stress involved in mediating degradation of damaged cellular components. However, an
increasing amount of evidence demonstrates that there is not a single pathway that leads to
“classical” autophagy, rather many forms of autophagy have been reported to affect cell
growth and proliferation, for example, including an Atg5/Atg7-independent “alternative”
macroautophagy and Beclin-1-independent autophagy [93, 95, 125]. The proteomic analysis
of autophagic network in human cells identified a complex network of over 700 interactions
and more than 400 interacting proteins in this pathway suggesting requirement of different
intermediates for the diverse forms of autophagy observed in mammalian systems [126]. To
determine the molecular pathways critical to miR-34a-induced autophagy, in this chapter I
examined the involvement of key intermediates in the canonical autophagic pathway- Beclin1 which is involved in autophagosome formation; ATG5 and ATG7 which are involved in
autophagosome elongation and completion and ATG4 involved in LC3 processing and
recycling [96, 122]. I used lentiviral shRNA constructs to knockdown Beclin-1; siRNA
sequences to knockdown ATG5, ATG7 and ATG4, and doxycline inducible shATG7 PC3
cells to determine their effects of miR-34a induced autophagy and cell proliferation.

miR-34a-induced autophagy does not rely on Beclin-1 expression
Since, miR-34a increased Beclin-1 protein expression (chapter 6); I determined
whether miR-34a-induced autophagy is mediated through Beclin-1. A lentiviral shRNA was
used to knockdown Beclin-1 in PC3 cells and cells were then FACS sorted for GFP to get
PC3 shBeclin-1 cells. PC3 and shBeclin-1 cells were then transfected with N.C. or miR-34a
for 72 hours. Knockdown of Beclin-1 did not change cell morphology, whereas
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overexpression of miR-34a in shBeclin-1 cells induced similar morphological changes as
observed in PC3 cells with miR-34a overexpression (Fig. 39). As shown in Fig. 40, protein
(Fig. 40A) and mRNA (Fig. 41B) expression of Beclin-1 was decreased following lentiviral
infection, while ATG7 mRNA expression was unaffected (Fig. 41A). These results suggest
specific knockdown of Beclin-1 was achieved. I next examined the effects of Beclin-1
knockdown on miR-34a-induced autophagy by determining if conversion of LC3 to LC3II
occurred. My results demonstrate that miR-34a overexpression increases LC3II expression
(Fig. 40A lane 1 vs. 2) with or without Beclin-1 knockdown (Fig. 40A, lane 3 vs. 4),
suggesting that miR-34a induces autophagy independent of Beclin-1.
To determine if miR-34a still downregulates critical targets in Beclin-1 knockdown
cells, I examined the expression of its known targets, MET and Axl. As expected,
overexpression of miR-34a was still effective in inhibiting these targets as shown by decrease
in MET protein and mRNA expression (Fig. 40 and 41B) and decrease in Axl expression
(Fig. 41C) in shBeclin-1 cells. I also examined the effects of miR-34a on proliferation in
Beclin-1 knockdown cells and consistent with my previous data, miR-34a overexpression
decreased cell proliferation compared to N.C. (Fig. 42, column 1 vs. 2). Beclin-1 knockdown
also decreased cell proliferation compared to N.C. (Fig. 42, column 1 vs. 3); however, miR34a overexpression further decreased proliferation in shBeclin-1 cells (Fig. 42 column 3 vs.
4). Analysis of acridine orange positive (AO+) cells demonstrated an increase in AO+ cells
with miR-34a overexpression, irrespective of Beclin-1 knockdown (Fig. 43A). Additionally,
cell cycle analysis demonstrated a 5-fold increase in the sub G1 fraction of cells following
miR-34a overexpression in both control and shBeclin-1 cells (Fig. 44B).
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Figure 39 - Morphology of miR-34a overexpressing PC3 cells with Beclin-1 knockdown
PC3 and PC3 cells with shBeclin-1 were transfected with N.C. or miR-34a for 72h and bright
field microscopy was used to capture images at 10x magnification using Nikon camera.
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Figure 40 - Beclin-1 knockdown in PC3 cells
Western blot for Beclin-1, LC3B, MET and GAPDH are shown for PC3 and PC3 shBeclin-1
cells with N.C. or miR-34a transfection (A). mRNA expression was measured using SYBR
Green qPCR and plotted for Beclin-1 (B). * denotes p<0.05 as measured by t test.
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Figure 41 – mRNA expression analysis with Beclin-1 knockdown in PC3 cells
mRNA expression for ATG7, c-Met and Axl (A-C) was measured using SYBR Green qPCR
in PC3 and shBeclin-1 cells transfected with N.C. or miR-34a. * denotes p<0.05 as measured
by student’s t test.
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Figure 42 - Effects of miR-34a overexpression on proliferation in shBeclin-1 cells
Hoechst proliferation assay at different time points for PC3 and PC3 shBeclin-1 with N.C. or
miR-34a transfection is graphed. * denotes p<0.05 as measured by t test.
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Figure 43 - Acridine Orange and cell cycle analysis in PC3 cells with Beclin-1
knockdown and miR-34a overexpression
Acridine orange positive cells were quantified by Gallios FACS and plotted (A) at 72 hours
post N.C. or miR-34a transfection. Propidium iodide was used for cell cycle analysis at 72
hours post N.C. or miR-34a transfection and different phases are plotted (B). * denotes
p<0.05 as measured by student’s t test.
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These data suggest that miR-34a-induced effects on autophagy, cell proliferation, and
apoptosis are mediated in a Beclin-1-independent manner.

miR-34a induces ATG5/7-independent autophagy
I next determined whether ATG5 and ATG7, canonically involved in autophagosome
elongation and completion [122] were required for the form of autophagy observed upon
miR-34a overexpression. I used two sequences of siRNA to robustly knockdown ATG5 and
ATG7 expression in PC3 cells and then transfected them with N.C. or miR-34a. Success of
knockdown was determined by immunoblotting and qPCR. ATG5 and ATG7 were reduced
more than 90% at the protein (Fig. 44A and Fig. 45A) and mRNA (Fig. 44B and Fig. 45B)
levels by corresponding siRNAs. The mRNA expression of ATG7 in siATG5 (Fig. 44C) and
ATG5 in siATG7 (Fig. 45C) cells is unaffected, suggesting specificity of knockdown of the
targeted gene. Knockdown of ATG5 and ATG7 did not change cell morphology whereas
overexpression of miR-34a in siATG5 and siATG7 cells induced similar morphological
changes as observed in PC3 cells with miR-34a overexpression (Fig. 46 and Fig. 47). As
expected, siATG5 and siATG7 decreased LC3II levels compared to N.C. (Fig. 44A and
45A, lane 1 vs. lane 3 and lane 1 vs. 5) confirming that knocking down these gene products
inhibits basal autophagy. I then examined the effects of miR-34a overexpression on
autophagy when either ATG5 or ATG7 is reduced by siRNA knockdown. As observed
previously with PC3 cells, miR-34a overexpression increased conversion of LC3 to LC3II as
indicated by increase in LC3II band compared to N.C. (Fig. 44A and 45A lane 1 vs. 2).
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Figure 44 - Effects of ATG5 knockdown in PC3 cells
Western blots for N.C., miR-34a and two siATG5 sequences with N.C. or miR-34a
transfection for ATG5, LC3B and GAPDH are shown (A). mRNA expression for ATG5,
ATG7, c-Met and Axl for N.C., miR-34a and two siATG5 sequences with N.C. or miR-34a
transfection after 72h was measured by SYBR Green qPCR and plotted. * denotes p<0.05 as
measured by t test.
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Figure 45 - Effects of ATG7 knockdown in PC3 cells
Western blots for N.C., miR-34a and two siATG7 sequences with N.C. or miR-34a
transfection for ATG7, LC3B and GAPDH are shown (A). mRNA expression for ATG7,
ATG5, c-Met and Axl for N.C., miR-34a and two siATG7 sequences with N.C. or miR-34a
transfection after 72h was measured by SYBR Green qPCR and plotted. * denotes p<0.05 as
measured by t test.
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Figure 46 - Morphology of miR-34a overexpressing PC3 cells with ATG5 knockdown
PC3 and PC3 cells with siRNA sequences of ATG5 were transfected with N.C. or miR-34a
for 72h and bright field microscopy was used to capture images at 10x magnification using
Nikon camera.
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Figure 47 - Morphology of miR-34a overexpressing PC3 cells with ATG7 knockdown
PC3 and PC3 cells with siRNA sequences of ATG7 were transfected with N.C. or miR-34a
for 72h and bright field microscopy was used to capture images at 10x magnification using
Nikon camera.
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Surprisingly, in the cells in which either ATG5 or ATG7 is reduced, miR-34a overexpression
still increased LC3II levels compared to N.C. (Fig. 44A and 46A, lane 3 vs. 4 and lane 5 vs.
6). This result suggests that miR-34a-induced autophagy is independent of ATG5 and ATG7.
Interestingly, miR-34a overexpression itself was sufficient to decrease ATG5 protein (Fig.
44A lane 1 vs. 2), further suggesting that ATG5 is not involved miR-34a-mediated
autophagy. Both c-met (Fig. 44D and 46D) and Axl (Fig. 44E and 45E) mRNA levels were
decreased with miR-34a overexpression in siATG5 and siATG7 cells, demonstrating miR34a still downregulates these targets that are involved in mediating autophagy [105, 106]
To determine the effects of miR-34a on proliferation in cells with reduced ATG5 and
ATG7, a Hoechst proliferation assay was performed. Overexpression of miR-34a decreases
proliferation compared to N.C. (Fig. 48A and 48B column 1 vs. 2), consistent with my
previous data. Reduced ATG5 and ATG7 expression decreased basal autophagy and cell
proliferation compared to N.C. (Fig. 48A and 48B column 3 and 4 vs. column 1) consistent
with previous reports [107]. However, miR-34a overexpression further decreased
proliferation in cells with reduced ATG5 (Fig. 48A column 3 vs. 4 and 5 vs. 6) and ATG7
(Fig. 48B column 3 vs. 4 and 5 vs. 6). This result suggests that ATG5 and ATG7 affect
canonical autophagy and cell proliferation, but not miR-34a-induced autophagy and its effect
on cell proliferation.
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Figure 48 - Cell Proliferation in siATG5 and siATG7 cells with miR-34a overexpression
Hoechst proliferation assay at different time points for N.C., miR-34a and two siATG5 (A)
and two siATG7 (B) sequences with N.C. or miR-34a transfection is graphed. * denotes
p<0.05 as measured by student’s t test.
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To minimize potential effects due to transient transfection, I also examined PC3 cells
with doxycycline-inducible shATG7 to assess the effects of miR-34a overexpression when
ATG7 is stably reduced. Upon addition of doxycycline, ATG7 protein (Fig. 49A) and mRNA
(Fig. 49B) are decreased without affecting ATG5 mRNA levels (Fig. 51A), confirming the
inducible knockdown of ATG7. Overexpression of miR-34a in the absence or presence of
doxycycline (in which shATG7 was induced) led to similar morphologic alterations observed
by miR-34a transfection alone; changes similar to that observed in PC3 and siATG7 cells
with mR-34a overexpression (Fig. 50). As a control, miR-34a overexpression still decreased
mRNA levels of c-Met (Fig. 51B) and Axl (Fig. 51C) in both non-induced and shATG7
conditions. To examine the effects of shATG7 on miR-34a-induced autophagy, I determined
LC3II protein expression. Consistent with my results in PC3 transiently transfected with
siATG7, an increase in LC3II expression was observed with miR-34a overexpression in both
non-induced (Fig. 49A) and Dox-induced shATG7 (Fig. 49A lane 3 vs. 4) cells. This result
supports the previous data that miR-34a effects on LC3II are independent of decreased
ATG7 expression. Further, a decrease in cell proliferation was observed in non-induced cells
with miR-34a overexpression (Fig. 52 column 1 vs. 2). Similar to results obtained with
siATG7, shATG7 decreased proliferation compared to N.C. at 96 hours (Fig. 52 column 1
vs. 3) and miR-34a overexpression further decreases proliferation in cells with reduced
ATG7 at 96 hours (Fig. 52 column 3 vs. 4). Taken together, these data suggest that miR-34a
overexpression induces autophagy that is independent of decreased ATG5 and ATG7
expression.
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Figure 49 - Effects of miR-34a overexpression in doxycycline inducible shATG7 PC3
cells
Western blots for ATG7, LC3B and GAPDH (A) and mRNA expression for ATG7 (B) in
non-induced and Dox-induced shATG7 cells transfected with N.C. or miR-34a is plotted *
denotes p<0.05 as measured by student’s t test.
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Figure 50 - Morphology of miR-34a overexpressing in doxycycline inducible shATG7
PC3 cells
Non-induced and doxycycline-induced shATG7 PC3 cells with were transfected with N.C. or
miR-34a for 72h and bright field microscopy was used to capture images at 10x
magnification using Nikon camera.

116

Figure 51 – mRNA expression analysis with miR-34a overexpression in doxycycline
inducible shATG7 PC3 cells
mRNA expression for ATG5, c-Met and Axl was measured in non-induced and Dox-induced
shATG7 cells transfected with N.C. or miR-34a * denotes p<0.05 as measured by student’s t
test.
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Figure 52 - Cell Proliferation in doxycycline inducible shATG7 PC3 cells
Hoechst proliferation assay at different time points for PC3 shATG7 no Dox and +Dox with
N.C. or miR-34a transfection is graphed. * denotes p value <0.05 as measured by student’s t
test.
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ATG4 knockdown effects autophagy independent of miR-34a overexpression
Since, knockdown of ATG7 and ATG5, the intermediates involved in the
downstream processing of LC3II did not affect the form of autophagy induced by miR-34a
overexpression; I examined whether ATG4, a cysteine protease involved upstream in the
conversion of pro-LC3 to LC3I is required for miR-34a induced autophagy. ATG4 has four
isoforms, ATG4A, ATG4B, ATG4C and ATG4D with overlapping and distinct functions. I
used siRNA sequences to knock down all four isoforms of ATG4 in PC3 cells and then
transfected the cells with either control (N.C.) or miR-34a mimics for 72 hours. The
overexpression of miR-34a in PC3 cells led to altered cellular morphology that was similar to
that observed with previous knockdowns or by overexpression of miR-34a alone; however,
knockdown of ATG4 alone induced morphological changes with cells appearing larger and
flattened (Fig. 53) compared to control cells. Overexpression of miR-34a in siATG4 cells
further altered the morphology of the cells with increases in cell size and in the perinuclear
region (Fig. 53). Next, I prepared protein lysates and performed immunoblotting for different
ATG4 isoforms. All isoforms of ATG4 (A-D) were reduced with siRNA sequences
confirming that the knockdown was efficient in decreasing ATG4 expression (Fig. 54A).
LC3II expression was increased with miR-34a overexpression compared to N.C. cells.
However, knockdown of ATG4 alone increased LC3II expression, while the overexpression
of miR-34a in siATG4 cells further increased LC3II expression (Fig. 54A). This result
suggests that knockdown of ATG4 itself has effects on increasing LC3II levels, independent
of autophagy induced by miR-34a. Cell cycle analysis demonstrated increases in the sub G1
fraction of cells and decrease in S-phase following miR-34a overexpression in both control
and siATG4 cells (Fig. 54B).
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Figure 53 - Morphology of PC3 cells with ATG4 knockdown and miR-34a
overexpression
PC3 cells were transfected with control siRNA or ATG4 siRNAs and then after 24 hours,
transfected again with N.C. or miR-34a mimics and bright field images were taken with
Nikon digital camera.
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Figure 54 - Effects of ATG4 knockdown in PC3 cells
PC3 cells were transfected with control siRNA or ATG4 siRNAs and then after 24 hours,
transfected again with N.C. or miR-34a mimics. After 72 hours of miRNA transfection, cells
were harvested for protein for immunoblotting with ATG4 antibodies (ATG4A, 4B, 4C and
4D) and LC3B (A); for cell cycle analysis with PI (B) and for acridine orange FACS analysis
(C).
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Analysis of acridine orange positive (AO+) cells demonstrated an increase in AO+ cells with
miR-34a overexpression (Fig. 54C), while ATG4 knockdown itself increased AO+ cells and
miR-34a overexpression further increased AO+ cells with ATG4 knockdown (Fig. 54C).
Confocal imaging with AO to visualize the acidic vesicular organelles further corroborated
the FACS results with increased accumulation of acridine orange in cytoplasm with miR-34a
overexpression compared to control (Fig. 55, top panel). ATG4 knockdown also increased
cytoplasmic acridine orange staining similar to FACS results and overexpression of miR-34a
further increased AO stained acidic vesicular organelles in ATG4 knockdown cells (Fig. 55,
bottom panel). These results suggest that ATG4 knockdown has effects on impaired
autophagy with increased accumulation of LC3II and acridine orange positive cells
independent of miR-34a and overexpression of miR-34a can induce autophagy even with
ATG4 knockdown.

Discussion
Results from chapters 6 and 7 provide definitive evidence that overexpression of
miR-34a induces autophagy, with both molecular markers (e.g., increase in lipidation of LC3
to form LC3II, increase in acidic vesicular organelles) and morphologic criteria (presence of
autophagosomes and autolysosomes by TEM) occurring (Figures 35-38, 40, 44-45 and 49).
However, as discussed in the Introduction, recent studies demonstrate that molecular
pathways leading to autophagy are diverse, suggesting there may not be a single “canonical”
pathway. In this chapter, I demonstrate that the form of autophagy induced with miR-34a
overexpression does not rely on the expression of Beclin-1, ATG5 or ATG7, whose gene
products “classically” play essential roles in mediating autophagy following nutrient
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Figure 55 - Acridine Orange staining in PC3 cells with ATG4 knockdown and miR-34a
overexpression
PC3 cells were transfected with control siRNA or ATG4 siRNAs and then after 24 hours,
transfected again with N.C. or miR-34a mimics. After 72 hours of miRNA transfection,
acridine orange was added for an hour and cells were fixed with 4% paraformaldehyde and
sucrose solution. Fixed cells were then imaged with confocal microscope at 20X
magnification.
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starvation, metabolic stress or by chemotherapeutic agents [92, 124] though possible effects
of incomplete knockdown cannot be excluded. ATG4 knockdown has effects on autophagy
independent of miR-34a overexpression.
My results with ATG5 and ATG7 agree with those of Nishida et al., who first
reported an Atg5/Atg7-independent “alternative” macroautophagy in which autophagosomes
and autolysosomes were still observed in mouse cells with Atg5 or Atg7 knockout [95].
However, lipidation of LC3 to form LC3II did not occur in this alternative autophagy
observed in their Atg5-/- or Atg7-/- MEF cells [95]. Thus, autophagy I observe has some of the
characteristics of being ATG5/ATG7 independent; however robust increase in LC3II
expression in both siRNA and shRNA mediated knockdown of ATG5 and ATG7
respectively, suggest that additional molecular intermediates may play a role in promoting
this “non-canonical” autophagy.
Since, miR-34a overexpression increased Beclin-1 protein expression, I expected
Beclin-1 knockdown to inhibit miR-34a-induced autophagy. Surprisingly, miR-34a still
increased LC3II expression in shBeclin-1 cells similar to what was observed in control PC3
cells overexpressing miR-34a. ATG4 is involved in LC3 processing and recycling. A recent
study in CML demonstrated that ATG4B is a direct target of miR-34a and is overexpressed
in CML [144]. Knockdown of ATG4B led to increase in LC3II and p62 indicative of
impaired autophagy [144]. I did not observe decrease of ATG4B protein levels with miR-34a
overexpression suggesting that it might not be a target of miR-34a in this system. My results
with the knockdown of all four isoforms of ATG4 increased LC3II with increased
accumulation of acidic vesicular organelles as determined by acridine orange staining
suggesting that ATG4 knockdown could have separate effects on autophagy that are different
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from miR-34a-mediated-autophagy. These results suggest that the form of autophagy
induced with miR-34a requires different intermediates than those involved during the
canonical autophagy.
Either Axl or MET inhibition is known to induce autophagy in diverse tumor cell
lines [105, 106]. These studies however, did not demonstrate whether canonical or noncanonical form of autophagy was induced upon Axl or MET inhibition. My results
demonstrate that overexpression of miR-34a still inhibited MET and Axl expression even in
Beclin-1 or ATG5/ATG7 knockdown cells suggesting that downregulation of these targets
could be involved in miR-34a-mediated autophagy. Inhibition of autophagy genes studied in
this chapter decreased cell proliferation; however overexpression of miR-34a causes further
decrease in proliferation in Beclin-1 or ATG5/ATG7 knockdown cells. These results
implicate a role of miR-34a-mediated autophagy in decreasing cell proliferation either alone
or in combination with apoptosis that needs to be further examined.
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Chapter 8
Expression of miR-34a in Human Prostate Cancer Samples
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In this dissertation, I have determined that miR-34a is downregulated in metastatic prostate
cancer cell lines and its delivery in in vivo models is effective in decreasing tumor growth.
Overexpression of miR-34a can induce non-canonical form of autophagy in cell line models.
The relationship between miR-34a expression and autophagy in prostate cancer clinical
samples is not known. Also, data supporting inverse correlation of miR-34a expression with
disease aggressiveness suggests a trend toward decreased miR-34a expression with
increasing Gleason score [89]. Previous studies using publically available datasets or qPCR
for miR-34a expression have reported decreased miR-34a in prostate cancer with further
decreases in expression with PCa progression [89, 127]. However, methods used in these
studies show large variations in miR-34a expression providing no visualization of expression
in different cell types. In this chapter, I determined miR-34a expression in human prostate
cancer samples by in situ hybridization that allowed for direct visualization of miR-34a
expression in normal prostate cells vs. prostate cancer tissue. Tissue microarrays (TMAs)
from different stages and grades of PCa provide a large cohort of clinical specimens that can
be stained with miR-34a and quantified to determine whether there is inverse correlation in
miR-34a expression with progressive PCa.

Expression of miR-34a is decreased in human prostate cancer specimens
To examine miR-34a expression in human prostate gland and cancer tissue, I received
human PCa samples from the Department of GU Medical oncology. H&E and in situ
hybridization (ISH) was performed on these samples that allowed visualization of
heterogeneity and tissue-specific identification of miR-34a expression. Similar areas from
H&E and ISH slides were imaged. High expression of miR-34a is observed in the normal
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prostate gland, with expression almost exclusively in the basal cell layer (Fig. 56A and 56E,
inset, 56B and 56F, inset) while the luminal cells do not stain for miR-34a in the normal
gland (Fig. 56A and 56E, inset, 56B and 56F, inset). In the tissue in which normal prostate
gland and adjoining prostate cancer are present (Fig. 56C and 56D), miR-34a expression is
lost in the cancerous tissue (Fig. 56G and 56H). This result suggests that there is a decreased
miR-34a expression in human PCa samples.

Results from a small sample set suggest that miR-34a expression is decreased in
prostate cancer compared to normal gland. More samples would be required to do miR-34a
staining and quantification of expression to determine whether miR-34a expression decreases
with disease progression. In situ hybridization demonstrates that miR-34a has differential
expression in basal vs. luminal cells of the prostate gland. As discussed in Introduction
(Chapter 1), it has been demonstrated that PCa can arise from both luminal and basal cells in
Pten-null mouse model and there is evidence of basal to luminal cell differentiation [12]. It
remains to be determined whether loss of miR-34a occurs in prostate cancer arising from
basal cells and whether re-expression of miR-34a in luminal cells will inhibit cancer
development. Loss of miR-34a could be one of the mechanisms of aberrant activation c-Myc
that can promote cancer initiation. It will be the focus of future studies to determine the
expression of miR-34a targets in different prostate cell types and in cancer tissue. This study
highlights the further need to understand the regulation of miR-34a expression in prostate
gland for better understanding of its role in cancer initiation and development.
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Figure 56 - miR-34a is downregulated in PCa
The expression of miR-34a was measured by in situ hybridization. Similar areas for H&E
(A-D) and miR-34a ISH (E-H) were captured and are shown above.
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Chapter 9
Discussion
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When organ-confined, prostate cancer is curable. However, when prostate cancer
metastasizes, most frequently to the bone, it is almost always lethal. Despite newly approved
FDA therapies that prolong survival, increased lifespan for men with metastatic PCa is
relatively minimal. The failure of therapies could be attributed to development of de novo
resistance mediated by interactions with the microenvironment or acquired resistance
mediated by alterations in the tumor cell that promote tumor growth. It is thus essential to
develop novel strategies for treatment of advanced disease, which will require a better
understanding of PCa progression and tumor growth in the bone.
In this dissertation, I have focused on understanding several aspects of prostate cancer
biology related to regulation of specific tyrosine kinases that play a role in PCa progression
and targeting multiple gene products associated with metastatic disease. The thesis raised
issues with respect to targeting individual molecules, demonstrated the promise of using
miRNA-mediated strategies to target multiple molecules and revealed the complicated interrelated biologic consequences of this targeting, apoptosis and autophagy.

Activation of IGF-1/1R pathway induces ligand-independent delayed MET activation
In cancer, several growth factor receptors and receptor tyrosine kinases are aberrantly
expressed contributing to tumor development and progression [128, 129]. One mechanism of
receptor activation is mediated through binding of its ligand and activation of downstream
signaling pathway [130]. However, recent studies have identified ligand-independent
receptor cross talk mechanisms in cancer. There are numerous mechanisms by which this
occurs, including amplification of non-targeted receptor with overlapping functions,
activation of a non-targeted receptor, or reactivation of a targeted receptor [41, 43, 131]. A
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well-studied example is crosstalk between EGFR and MET. EGFR activation has been
demonstrated to lead to delayed MET activation in non-small cell lung cancer cell lines [43],
MET is amplified after erlotinib or gefinitib treatment in lung tumors [42, 132]. Thus, to
understand which therapies might be effective in combination and/or how to best use targeted
therapies, cross talk mechanisms need to be better understood. A theoretical publication
[133] suggested specific classes of receptors that perform overlapping functions and are
likely to be activated upon inhibition of a targeted kinase. Biologically, my goal was to
determine if kinases known to be activated and have targeted inhibitors in clinical trial would
lead to cross talk that might explain the lack of success of some of these trials. In prostate
cancer and in PCa bone metastasis, IGF-1R and MET receptors are overexpressed and
predict poor prognosis [36, 40, 112, 113, 134, 135]. Multiple inhibitors to both of these
signaling axes are in clinical trials [113, 136]. These trails have generally led to failure, both
through development of resistance and re-activation of targets. Thus, to determine whether
re-activation of targeted kinase occurs through cross talk with other receptors, I studied IGF1R mediated MET activation in Chapter 3 of this dissertation. I demonstrated that in cell
lines that express both IGF-1R and MET receptor tyrosine kinases, activation of IGF-1R by
IGF-1 induces delayed phosphorylation of MET which is independent of its ligand, HGF.
This implies that in cancers where both receptors are present on cancer cells, presence of
IGF-1 in the tumor microenvironment can lead to MET phosphorylation.
It was next important to determine if the phosphorylation led to activated MET
functions and further, to examine if IGF-1R biologic functions were mediated through MET.
Activation of IGF-1/1R and MET pathway was biologically functional as determined by
phosphorylation of catalytic tyrosine sites on MET indicative of full MET activation and also
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demonstrated by activation of downstream Akt, Src and MAPK signaling pathways.
Activation and expression of IGF-1R was essential for IGF-1 to phosphorylate MET as in the
absence of IGF-1R this delayed MET activation was abolished. This result is similar to
findings of Dulak et al. on cross talk between EGFR and MET, where they demonstrate that
activation of EGFR by EGF leads to MET activation [43]. However, unlike their result, MET
expression did not increase upon IGF-1 stimulation.
Dasatinib (a multi-targeted pan Src family kinase inhibitor)-mediated inhibition of
Src phosphorylation diminished both IGF-mediated (Chapter 3) and EGF-mediated-MET
[43] activation, demonstrating that activated Src serves as the central regulator of atleast
several receptor cross talk mechanisms. In line with this observation, constitutive activation
of Src was sufficient to induce MET phosphorylation even in the absence of IGF-1.
However, in this study it was not determined whether Src directly mediates MET activation. I
speculate that activation of Src enhances the activity of a transcription factor that then
induces transcription of unknown protein/s that interact with MET and trigger its
phosphorylation either directly or indirectly through other adaptor or MET-binding partner/s.
The results from treatment of cells with pan-transcription inhibitor actinomycin D that
abolished IGF-1 induced MET phosphorylation further corroborates the role of
transcriptional component/s in mediating IGF-1/1R induced MET activation. Dulak, et al.
also implicate transcriptional involvement of unknown factor/s in mediating growth factor
cross talk with EGF and MET [43]. It will be the focus of future studies to determine if
common transcription factors are involved in cross talk among receptors, and then identify
MET binding proteins in the complex that could be involved in mediating IGF-1/1R to MET
activation, as IGF-1R does not directly lead to MET phosphorylation. These results are
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summarized in the model of IGF-1/1R induced MET phosphorylation that requires Src
activation and unknown transcriptional mediators and further leads to activation of
downstream signaling pathways including migration (Fig. 57).
Though several mechanisms for ligand independent MET activation including
upregulation of plexins, G-coupled receptors, integrin binding, have been reported, I
investigated whether integrins are involved in inducing delayed MET phosphorylation, as
β1integrins interact with MET, and are themselves known to be important in PCa bone
metastasis [137] and have been implicated in MET activation [41]. For these experiments, I
determined whether cross talk between IGF-1R and MET still occurred in integrin β1
knockdown cells (PC3 cells). However, knockdown of integrin β1did not inhibit IGF-1induced MET phosphorylation suggesting integrin β1 was not involved. It remains to be
investigated whether other integrins for example, integrin β3 implicated in prostate cancer
progression [138] could be a mediator in IGF-1/1R-induced MET activation. I did not study
bi-directional IGF-1/1R activation upon HGF stimulation and this will be another area for
exploration to further understand receptor cross talk mechanism.
In summary, this study adds to previous works suggesting combinatorial targeting of
multiple tyrosine kinases as a better therapeutic approach in cancers where more than one
kinase is activated. MET activation through ligand-independent mechanisms in different
cancers indicates that MET activation might serve as a converging node required by other
kinases to mediate their biological effects. This is highlighted in my study where MET
knockdown abolishes IGF-1-induced migration.
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Figure 57 - Model of Ligand Independent MET activation by IGF-1/1R pathway
This figure illustrates that activation of IGF-1R by IGF-1 increases MET phosphorylation but
not its expression and does not require MET ligand, HGF but requires Src activation and
transcription (bold arrows) through an unidentified factor X.
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Taken together, these findings implicate that cross talk mechanism between receptor
tyrosine kinases might be responsible for failure of small molecule ATP inhibitors against
targeted-kinases. There could be common transcription-mediated pathways involving
unidentified transcription factors and proteins/kinases that activate more than one RTK and
understanding these pathways as well as identifying the common transcription factor might
be one approach to targeting multiple kinases. These findings further implicate that targeting
multiple aberrantly expressed kinases through strategies that not only inhibit their activation
but also their expression might be more important in cancer therapeutics.

miR-34a is decreased in metastatic PCa cell lines and its delivery decreases prostate
tumor growth
The above study had several implications, as described, but led to questions such as,
elimination of cross talk through downregulation of an activated receptor; and are in line with
the seeming necessity for inhibiting multiple targets for better therapeutic efficacy. Thus,
delivery of tumor suppressive miRNAs, which downregulate the expression of multiple
targets is now an emerging approach with therapeutic promise. In Chapters 4 and 5 of this
dissertation, I focused on miR-34a, a miRNA downregulated in many cancers and considered
a tumor suppressive miRNA since it targets many oncogenic proteins. Specifically, this
miRNA was chosen in prostate cancers as it downregulates MET, thus extending my
previous work, miR-34a also downregulates Axl, an emerging target for advanced-stage PCa
and c-Myc, an important oncogene de-repressed at earlier stages of PCa, and has additional
targets not assessed in this thesis, such as, Bcl-2, Notch1, cyclin D1, CDK4, CDK6, etc.
which may augment apoptosis and cell cycle arrest [75, 139]. Increased expression of MET,
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Axl and Myc has been reported in primary and advanced PCa [25, 38, 40, 46-48, 51, 117] as
discussed in Introduction (Chapter 1) section. In the last few years, targeting MET activation
is an attractive area of research in pre-clinical and clinical studies. However, MET inhibitors
have limited success and are associated with severe toxic effects in clinical trials [4].
Recently, the dual VEGFR2 and MET small molecule inhibitor, Cabozatinib failed to
demonstrate statistical significance in prolonging overall survival (OS) in Phase III clinical
trial of men with mCRPC. Axl inhibitors have just entered phase 1 clinical trial [140] and
have not been tested for use with advanced PCa. c-Myc being a transcription factor is not
considered as a “druggable” target and targeting Myc-dependent synthetic lethal interactions
is being further explored [54]. This presents a need for a therapeutic strategy that will inhibit
multiple targets promoting growth and progression in prostate cancer. Importantly, miR-34a
inhibited all three targets in vitro and in vivo in PCa as shown in Chapter 4 and 5 results,
making it a useful candidate for potentially inhibiting tumor growth in bones. These data is in
agreement with previous reports examining these targets in breast, non-small cell lung,
colorectal, and prostate cancer [45, 53, 82-85, 87], although none of these targets have been
examined simultaneously before my studies. Thus, miR-34a was a potential candidate for
replacement therapy that would inhibit prostate tumor growth in the bone.
The first issue to be addressed was the relationship between miR-34a expression and
aggressiveness and metastatic potential of well-characterized tumor cell lines. My in vitro
data demonstrated that miR-34a expression decreases with aggressiveness and metastatic
potential of PCa cell lines. I further demonstrated that miR-34a effects properties associated
with metastasis including decrease in migration, invasion, proliferation; cell cycle changes
and increase in apoptosis, demonstrating direct anti-tumor effects. Although other groups
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have shown that miR-34a induces senescence [141], I did not observe senescence upon miR34a overexpression by using SA-β-galactosidase assay (data not shown).
During the course of my studies, the attractiveness of this approach became obviously
popular, as many studies in miR-34a in prostate and other cancers have appeared since my
work was initiated. But several unanswered questions still remained, including whether
delivery of miR-34a would affect growth of bone metastasis, which as noted many times in
this thesis is the major killer from prostate cancer. To address the effects of miR-34a delivery
on tumor growth in the bone I used an intra-femoral mouse model for my therapeutic
experiment and demonstrated that miR-34a delivery through chitosan nanoparticles
decreased tumor growth. Due to lack of current animal models for PCa that lead to
spontaneous bone metastasis, I used direct injection of tumor cells in the femur to best
represent PCa bone metastasis. This is the first study to demonstrate a therapeutic benefit of
miR-34a in the treatment of established prostate tumors in the bone. Although Liu et al. used
miR-34a delivery for orthotopic PC3 tumors in mice [84], my study provides evidence to
support miR-34a delivery in advanced PCa as well. Krzeszinski et al. recently showed that
delivery of miR-34a decreases bone metastases of breast cancer and melanoma cell line in
intra-cardiac mouse model by inhibiting osteoclast activity [74]. They used genetic and
pharmacologic model to demonstrate that decreased bone metastasis was due to altered
expression of miR-34a in the bone microenvironment, providing convincing evidence that,
for these models, that primary effectiveness was due to a single protein in osteoclasts, Tgif2,
and emphasizes the importance of targeting the tumor microenvironment [74]. However,
therapies in osteoblastic PCa bone metastasis that target primarily microenvironment, as
determined in part, by their failure to reduce PSA and tumor remaining in bone scans, such as
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cabozatinib and Rad 223 [4, 60] suggest that targeting microenvironment in PCa bone
metastases is insufficient to have prolonged efficacy and overall survival. Thus, the goal
from the beginning of my studies was to attempt to target tumor cells. My findings along
with those of Krzeszinski, et al suggest that miR-34a can be useful in targeting both the
tumor as well as the microenvironment, and may account for growth inhibition in bone that
exceeded the tumor reduction in sub-cutaneous studies. A potential role of Tgif2 inhibition in
prostate cancer bone metastasis models would be an interesting subject of future work.
In previous studies, delivery of downregulated miRNAs has been shown to inhibit
tumor growth in different in vivo models without any severe toxic effects [68, 75, 85, 86, 88].
Likewise, in my study, I observed that delivery of miR-34a led to inhibition of tumor growth
without any toxic effects in the mice. Since, no current therapies are effective in treating PCa
metastatic to bone without severe toxicities; this study presents an alternative treatment
strategy to circumvent this problem. A more detailed understanding of the biology resulting
from this strategy will be required if miR-34a delivery is to become therapeutically relevant.
This dissertation did not address the mechanism of miR-34a downregulation in PCa,
which can be explored in future research. Previous studies have reported that miR-34a is
regulated by p53-dependent and p53-independent mechanisms [79, 80, 139]. p53 is mutated
in PC3 and PC3MM2 cells, indicating that loss of p53 might be involved in miR-34a
downregulation in these cell lines [84]. However, since p53 mutations are not as common in
PCa (>20%) and generally occur at later stages [6, 142], other mechanisms including
hypermethylation of miR-34a promoter are very likely be responsible for downregulation of
its expression, given the frequency of miR-34a decreases I observed in human specimens.
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My results from in vivo studies demonstrate stronger induction of apoptosis by miR-34a
delivery compared to miR-34a overexpression in vitro, which increased apoptosis by 2030%. Downregulation of miR-34a targets, MET and Axl, studied in this dissertation have led
to increase in apoptosis and autophagy leading to decrease in cell viability [105, 106]. This
led me to speculate whether autophagy along with apoptosis could be involved in miR-34a
overexpression mediated decrease in cancer cell growth.

Overexpression of miR-34a induces non-canonical form of autophagy
A major part of my thesis focused on autophagy, for several reasons. As discussed
above, knockdown of either MET or Axl in different systems has been shown to induce
autophagy. Further, overexpression of miR-34a induced morphological characteristics,
including increases in cell size and with transmission electron microscopy, autophagosomes
and autolysosomes were detected upon miR-34a overexpression. As autophagy has received
considerable attention both for its role in cellular survival and potentially promoting
tumorigenesis, as well as its role in cellular death and tumor suppression, understanding
whether autophagy occurred and by what mechanism became important to my work.
Prolonged treatment with targeted molecular therapy induces autophagy leading to cell death
[97] and treatment with chemotherapeutic agent, Rottlerin induces autophagy associated with
cell death in different cancer cell lines [99, 120], further emphasizing the complex biological
effects of autophagy in cancer models. Since, my studies involved prolonged miR-34a
treatment, with miR-34a delivered every three days in in vivo studies and the overexpression
in vitro was over a time course of four days, it was important to assess whether autophagy
was induced in my system.
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The goal of my work with miR-34a-induced autophagy was to determine whether
autophagy inhibited or augmented miR-34a therapeutic effects. To do this it was important to
first inhibit autophagy and then use miR-34a overexpression to determine its effects on cell
proliferation and autophagy marker, LC3II expression. I used bafilomycin A1 that inhibits
late stage autophagy by preventing fusion between autophagosomes and lysosomes.
However, bafilomycin is a toxic chemical with other cellular targets that led to more than
90% cell death in PC3 cells (data not shown). To overcome the toxicities of chemical
inhibitors, I used knockdown of genes involved in the autophagy pathway to inhibit
autophagy and then overexpress miR-34a. Knockdown of Beclin-1, ATG5, ATG7 and ATG4
was not very toxic to the cells and effective in inhibiting basal autophagy. However miR-34a
overexpression still induced autophagy even with the knockdown of these genes with
increase in LC3II and decrease in cell proliferation. Thus, implicating that miR-34a did not
require these genes for mediating its molecular and biological effects.
Nishida et al. reported an ATG5/ATG7-independent macroautophagy that did not
increase LC3II expression [95]. Contrary to this finding, my results with miR-34a
overexpression demonstrate increase in LC3II even in ATG5 and ATG7 knockdown cells.
Scarlatti, et al. reported that resveratrol (Res) induces Beclin-1-independent non-canonical
autophagy in breast cancer cells with increase in LC3II upon Res treatment in Beclin-1
knockdown cells [125]. Similar to this finding, my results in Chapter 7 demonstrate increase
in LC3II in shBeclin-1 cells with miR-34a overexpression. These data suggest existence of
compensatory mechanism through other E1 and E3-like enzymes that are involved in
mediating LC3 conversion upon autophagy induction by miR-34a. Different intermediates
could be recruited to induce autophagy as Liu et al. demonstrated that miR-34a inhibits
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autophagy under starvation or chemotherapy that enhances cell death by inhibiting HGMB1
expression in retinoblastoma cells [91]. This led me to speculate that under conditions of
serum starvation, miR-34a could inhibit protective autophagy that promotes cell survival
whereas in complete growth medium conditions, miR-34a overexpression induces a form of
autophagy that promotes cell death.
Taken together, these findings further implicate that diverse forms of autophagy are
induced with different cellular stresses through several intermediates that might lead to
different biological effects. Identification of key molecular intermediates involved in the
form of autophagy induced by miR-34a overexpression will be important in delineating the
mechanism and biological effects of miR-34a-mediated autophagy. ATG4 is a cysteine
protease that mediates conversion of LC3 to LC3I that is further processed to LC3II, a
lipidated of LC3, and is also required in deplidation to LC3I [143]. Knockdown of ATG4
homologue, ATG4B in chronic myeloid leukemia (CML) leads to impaired autophagy with
increase in LC3II and decrease in cell viability and cell proliferation [144]. It was further
demonstrated that miR-34a directly targets and inhibits ATG4B though the effects of miR34a on autophagy were not examined [144]. These results suggest that downregulation of
ATG4B could lead to impaired autophagy. To determine whether ATG4B was targeted by
miR-34a in my system and could be involved in miR-34a mediated autophagy, I performed
knockdown of ATG4B and then overexpressed miR-34a to assess the effects on autophagy.
The other homologues of ATG4 including ATG4A, ATG4C and ATG4D with overlapping
functions [143] could negate the effects of miR-34a inhibition of ATG4B and thus, I used
siRNAs to knockdown all four isoforms of ATG4 which led to increased LC3II and acridine
orange positive cells indicative of autophagy. In my studies, ATG4B or the other isoforms do
142

not appear to be a direct target of miR-34a. Future studies could focus on knockdown of
individual homologues to examine the involvement of ATG4 isoforms in miR-34a-mediated
autophagy or their effects on autophagy independent of miR-34a.
Downregulation of miR-34a targets, Axl and MET can induce autophagy through
unidentified mechanisms [105, 106]. In this study, I tried to determine at least in part, the
mechanism of autophagy induced through downregulation of these receptor tyrosine kinases
by miR-34a. Future work will focus on determining whether downregulation of MET and
Axl alone or in combination is sufficient to induce the form of autophagy as observed with
miR-34a overexpression. As summarized in Figure 58, miR-34a could be mediating its
effects indirectly through inhibition of RTKs, Axl and MET. Other autophagy intermediates
including Beclin-1, ATG5 and ATG7 are not involved in miR-34a-mediated autophagy while
ATG4 knockdown itself affects autophagy independent of miR-34a overexpression (Fig. 58).
There could be other direct targets of miR-34a involved in autophagy induction and it will be
the focus of future studies to identify direct or indirect modulators of miR-34a-induced
autophagy.
This study highlights that miR-34a could have different effects on autophagy in
different cellular and tumor contexts under different conditions and it will be important to
determine whether autophagy is induced or inhibited in patients on MRX34 clinical trial, to
understand the therapeutic effects of miR-34a delivery.
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Figure 56 - Model of miR-34a-induced autophagy
This figure illustrates that miR-34a overexpression induces apoptosis and a form of
autophagy that is independent of Beclin-1, ATG5 and ATG7, which are involved in
conversion of LC3I to LC3II (Blue dotted arrow). Autophagy induced with miR-34a
overexpression could be through inhibition of RTKs, Axl and MET that can then lead to
apoptosis, autophagy (Black dotted arrows) and decreased cell proliferation. Alternatively,
other direct targets of miR-34a could lead to autophagy induction. Downregulation of ATG4
(red dotted arrow) led to increase in LC3II independent of miR-34a.
Modified with permission from “Randall-Demello S, Chieppa M and Eri R (2013). Intestinal
epithelium and autophagy: partners in gut homeostasis. Frontiers in Immunology. Doi
10.3389/fimmu.2013.00301.”
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Summary and Future Directions
In conclusion, in this dissertation I have demonstrated ligand-independent delayed
MET activation through IGF-1/1R pathway that requires IGF-1R, activated Src and
transcription. Future studies will focus on identifying the transcriptional intermediate that
mediates MET phosphorylation by identifying binding proteins in MET complex.
Clinical and in vitro data implicates an inverse relationship between miR-34a
expression and prostate cancer progression with decreased in miR-34a expression in
metastatic prostate cancer cell lines. I further demonstrated that decreased miR-34a
expression leads to upregulation of targets that promote PCa progression, and in vivo miR34a replacement therapy could be a useful treatment for advanced PCa. Overexpression of
miR-34a induced a form of non-canonical autophagy independent of ATG5, ATG7 and
Beclin-1 expression. Further studies will focus on examining involvement of other direct
targets of miR-34a including growth factor receptors in mediating the form of autophagy
induced by miR-34a.
I demonstrated that miR-34a delivery could be a therapeutic strategy for PCa bone
metastasis. It would require more studies with other xenograft models to determine the
efficacy of miR-34a treatment for clinical applications. Also, it will be important to study
whether prolonged treatment with miR-34a results in residual tumor resistant to miR-34a
therapy. It is possible that resistance to miR-34a therapy can arise upon longer treatment
duration and that will be an area of further exploration. Combination miRNA therapies
focusing on delivering two or more miRNAs downregulated in cancers can be developed to
test whether it will be more effective than single miRNA delivery. I studied expression of
IGF-1 and IGF-1R targeting miR-145 in prostate cancer cell lines (data not shown) as an
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extension to my current research. The expression of miR-45 is downregulated in prostate
cancer cell lines and its overexpression decreased IGF-1 secretion as well as phosphorylation
of IGF-1R (data not shown). Future studies can determine whether miR-145 modulates IGF1/1R signaling and whether dual miRNA delivery of miR-145 and miR-34a to target IGF1/1R pathway along with MET, Axl and c-Myc signaling axes in prostate xenograft models
will be more effective than single miRNA-delivery.
Inhibition of growth factor receptors could lead to different forms of autophagy as
demonstrated by downregulation of Axl and MET and antagonism of prolactin receptor [97,
105, 106] than autophagy mediated by targeting direct intermediates with different biological
consequences. This work attempted to understand the form of autophagy induced by miR34a and whether it was mediated indirectly through downregulation of some of these
receptors or directly through modulating essential autophagy genes. It can be further
examined whether single or combined knockdown of Axl and MET is sufficient to induce the
form of autophagy mediated by miR-34a overexpression. Further, inhibition of apoptosis and
cell proliferation in the presence and absence of miR-34a will help in defining the biological
effects of this non-canonical autophagy. Finally, determining the expression of autophagy
markers and whether miR-34a influences autophagy in patients would be useful in
understanding the therapeutic applicability of miR-34a delivery strategy for cancer treatment.
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